| |
|
HCV | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
| |
| 2. | The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration |
| |
Gidwani-Marszowski R1,2,3, Owens DK4,5, Lo J6, Goldhaber-Fiebert JD5, Asch SM4,7, Barnett PG6,4,5. Appl Health Econ Health Policy. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 5. | Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment |
| |
Voils CI1,2, King HA3,4,5, Thorpe CT6,7, Blalock DV3,8, Kronish IM9, Reeve BB4, Boatright C3, Gellad ZF3,10. Dig Dis Sci. 2019 Apr 29. doi: 10.1007/s10620-019-05621-7. [Epub ahead of print]
|
|
| |
| 6. | The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study |
| |
Trickey A1, Fraser H2, Lim AG2, Peacock A3, Colledge S3, Walker JG2, Leung J4, Grebely J5, Larney S3, Martin NK6, Hickman M7, Degenhardt L3, May MT8, Vickerman P7. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30085-8. doi: 10.1016/S2468-1253(19)30085-8. [Epub ahead of print]
|
|
| |
|
|
| |
| 8. | Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study |
| |
Bajis S1, Grebely J1, Cooper L2, Smith J2, Owen G2, Chudleigh A2, Hajarizadeh B1, Martinello M1, Adey S3, Read P4, Gilliver R4, Applegate T1, Treloar C5, Maher L1, Dore GJ1. J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112. [Epub ahead of print]
|
|
| |
|
|
| |
| 10. | Liver Fibrosis Determination |
| |
Lai M1, Afdhal NH2. Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.
|
|
| |
|
|
| |
| 12. | Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis |
| |
Back D1, Belperio P2, Bondin M3, Negro F4, Talal AH5, Park C3, Zhang Z3, Pinsky B3, Crown E3, Mensa FJ3, Marra F1. J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 16. | HIV and HCV screening among trauma patients |
| |
Simoncini GM1, Oyola-Jimenez J1, Singleton D1, Volgraf J2, Ramsey FV3, Goldberg A4. Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590. [Epub ahead of print]
|
|
| |
| 17. | Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2 |
| |
Rogal SS1,2,3, Yakovchenko V4, Waltz TJ5,6, Powell BJ7, Gonzalez R8, Park A9, Chartier M10, Ross D10, Morgan TR8, Kirchner JE11, Proctor EK12, Chinman MJ13,14. Implement Sci. 2019 Apr 8;14(1):36. doi: 10.1186/s13012-019-0881-7.
|
|
| |
| 18. | Health implications of sex trading characteristics in Long Beach, California, USA |
| |
Clingan SE1, Fisher DG2,3, Hardan-Khalil K4, Reynolds GL3,5, Huckabay L4, Costa C4, Pedersen WC2, Johnson ME6. Int J STD AIDS. 2019 Apr 8:956462419828138. doi: 10.1177/0956462419828138. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 22. | Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois |
| |
McLuckie C1,2, Pho MT3,4, Ellis K5, Navon L6,7, Walblay K8, Jenkins WD9, Rodriguez C10, Kolak MA11, Chen YT12, Schneider JA13, Zahnd WE14,15. Int J Environ Res Public Health. 2019 Mar 19;16(6). pii: E989. doi: 10.3390/ijerph16060989.
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 27. | Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015 |
| |
Abara WE1, Trujillo L2, Broz D2, Finlayson T2, Teshale E1, Paz-Bailey G2, Glick S3, Al-Tayyib AA4, Robinson WT5, Masiello-Schuette S6, Sey EK7, Anderson BJ8, Poe J Infect Dis. 2019 Mar 27. pii: jiz142. doi: 10.1093/infdis/jiz142. [Epub ahead of print]
J9, Braunstein S10.
|
|
| |
|
|
| |
|
|
| |
| 30. | Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia |
| |
Doyle JS1,2, Scott N2,3, Sacks-Davis R2, Pedrana AE2,3, Thompson AJ4,5, Hellard ME1,2,3; Eliminate Hepatitis C Partnership. Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15210. [Epub ahead of print]
Collaborators (10)
|
|
| |
| 31. | Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy |
| |
Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.
Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 34. | The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment |
| |
Woodward EN1,2, Matthieu MM3,4, Uchendu US5, Rogal S6,7,8, Kirchner JE3,9,10. Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.
|
|
| |
|
|
| |
|
|
| |
| 37. | Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy |
| |
Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.
Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
|
|
| |
|
|
| |
| 39. | Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017 |
| |
Bixler D1, Annambholta P2, Abara WE1, Collier MG1, Jones J2, Mixson-Hayden T1, Basavaraju SV2, Ramachandran S1, Kamili S1, Moorman A1. Am J Transplant. 2019 Mar 12. doi: 10.1111/ajt.15352. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
| 42. | Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review |
| |
Francis-Graham S1,2,3, Ekeke NA4, Nelson CA5, Lee TY5, Haj SE4, Rhodes T6, Vindrola C7, Colbourn T8, Rosenberg W9,4,10. BMC Health Serv Res. 2019 Mar 8;19(1):152. doi: 10.1186/s12913-019-3970-z.
|
|
| |
|
|
| |
| 44. | Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers |
| |
Sandmann L1,2, Dörge P1,2, Wranke A1,2, Vermehren J3,2, Welzel TM3,2, Berg CP4,2, Grottenthaler JM4,2, Weiss KH5,2, Langel J5,2, Sterneck M6,2, von Wulffen M6,2, Manns MP1,2, Wedemeyer H1,7,2, Hardtke S1,2, von Hahn T1,2. Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]
|
|
| |
|
|
| |
| 46. | Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study |
| |
Ide T1, Koga H2, Nakano M1, Hashimoto S3, Yatsuhashi H3, Higuchi N4, Nakamuta M4, Oeda S5, Eguchi Y5, Shakado S6, Sakisaka S6, Yoshimaru Y7, Sasaki Y7, Honma Y8, Harada M8, Seike M9, Maeshiro T10, Miuma S11, Nakao K11, Mawatari S12, Ido A12, Nagata K13, Matsumoto S14, Takami Y15, Sohda T16, Kakuma T17, Torimura T1. Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2. [Epub ahead of print]
|
|
| |
| 47. | Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection |
| |
Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
|
|
| |
| 48. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease |
| |
Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
|
|
| |
|
|
| |
| 50. | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease |
| |
Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
|
|
| |
|
|
| |
|
|
| |
| 53. | Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection |
| |
Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
|
|
| |
| 54. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease |
| |
Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
|
|
| |
| 55. | Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease |
| |
Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
|
|
| |
| 56. | Vitamin D deficiency and health-related quality of life in chronic hepatitis C |
| |
Palazzo D1, Biliotti E1, Esvan R1, Volpicelli L1, Franchi C1, Fontanelli Sulekova L1, Spaziante M1, Santori M1, Rugova A1, Rucci P2, Taliani G1. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076. [Epub ahead of print]
|
|
| |
| 57. | Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs |
| |
Day E1, Broder T2, Bruneau J3, Cruse S1, Dickie M4, Fish S4, Grillon C5, Luhmann N5, Mason K6, McLean E7, Trooskin S8, Treloar C9, Grebely J10. Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]
|
|
| |
| 58. | Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs |
| |
Childs E1, Assoumou SA2, Biello KB3,4,5, Biancarelli DL1,6, Drainoni ML1,2,6,7, Edeza A3,4, Salhaney P3, Mimiaga MJ3,4,5,8, Bazzi AR9. Harm Reduct J. 2019 Feb 11;16(1):14. doi: 10.1186/s12954-019-0286-6.
|
|
| |
| 59. | Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis |
| |
Kumthekar A1, Shull S2, Lovejoy TI2,3, Morasco BJ2,3, Chang M2,3, Barton J2,3. Int J Rheum Dis. 2019 Feb 6. doi: 10.1111/1756-185X.13479. [Epub ahead of print]
|
|
| |
| 60. | Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries |
| |
Ferenci P1, Bourgeois S2, Buggisch P3, Norris S4, Curescu M5, Larrey D6, Marra F7, Kleine H8, Dorr P9, Charafeddine M9, Crown E9, Bondin M9, Back D7, Flisiak R10. J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080. [Epub ahead of print]
|
|
| |
|
|
| |
| 62. | Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project |
| |
Kempf MC1, Ott C2, Wise JM2, Footman AP3, Araya BY3, Hardy CM4, Walker C4, Latham C5, Stockett R5, Daniels G5, Alexander M5, Lanzi RG3. Am J Prev Med. 2018 Nov;55(5S1):S112-S121. doi: 10.1016/j.amepre.2018.05.015.
|
|
| |
| 63. | Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection |
| |
Lawitz E1, Poordad F1, Anderson LJ2, Vesay M2, Kelly MM2, Liu H2, Gao W2, Fernsler D2, Asante-Appiah E2, Robertson MN2, Hanna GJ2, Barr E2, Butterton J2, Kowdley KV3, Hassanein T4, Sahota A5, Gordon SC6, Yeh WW2. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]
|
|
| |
| 64. | Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy |
| |
Grebely J1, Dore GJ2, Alami NN3, Conway B4, Dillon JF5, Gschwantler M6, Felizarta F7, Hézode C8, Tomasiewicz K9, Fredrick LM3, Dumas EO3, Mensa FJ3. Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 69. | JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1 |
| |
Shah ND1, Ventura-Cots M2, Abraldes JG3, Alboraie M4, Alfadhli A5, Argemi J6, Badia-Aranda E7, Soler EA8, Barritt AS 4th1, Bessone F9, Biryukova M10, Carrilho FJ11, Fernández MC8, Guiridi ZD10, El Kassas M12, Eng-Kiong T13, Farias A11, George J14, Gui W15, Thurairajah PH13, Hsiang JC13, Husic-Selimovic A16, Isakov V10, Karoney M17, Kim W18, Kluwe J19, Kochhar R20, Dhaka N20, Costa PM21, Nabeshima MA11, Ono SK11, Reis D21, Rodil A11, Domech CR8, Sáez-Royuela F7, Scheurich C19, Siow W14, Sivac-Burina N16, Dos Santos Traquino ES8, Some F17, Spreckic S16, Tan S22, Vorobioff J9, Wandera A17, Wu P22, Yakoub M12, Yang L15, Yu Y22, Zahiragic N16, Zhang C22, Cortez-Pinto H21, Bataller R23. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30073-4. doi: 10.1016/j.cgh.2019.01.026. [Epub ahead of print]
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 79. | Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients |
| |
Shoreibah M1, Romano J2, Sims OT3,4,5, Guo Y6, Jones D7, Venkata K2, Kommineni V2, Orr J8, Fitzmorris P1, Massoud OI1. J Clin Transl Hepatol. 2018 Dec 28;6(4):391-395. doi: 10.14218/JCTH.2018.00026. Epub 2018 Jul 11. |
|
| |
|
|
| |
| 81. | Machine learning models to predict disease progression among veterans with hepatitis C virus |
| |
Konerman MA1, Beste LA2, Van T3, Liu B4, Zhang X4, Zhu J4, Saini SD1,3, Su GL1,3, Nallamothu BK5,6, Ioannou GN7,8, Waljee AK1,3,6. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019. |
|
| |
| 82. | HCV therapy: no one to let behind |
| |
Bourlière M1, Pietri O2. Int J Antimicrob Agents. 2018 Dec 31. pii: S0924-8579(18)30380-7. doi: 10.1016/j.ijantimicag.2018.12.010. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 88. | Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure |
| |
Lim TR1,2, Hazlehurst JM3, Oprescu AI1, Armstrong MJ1,2, Abdullah SF4, Davies NP5, Flintham R5, Balfe P1, Mutimer DJ1,2, McKeating JA6, Tomlinson JW7. Clin Endocrinol (Oxf). 2018 Dec 26. doi: 10.1111/cen.13924. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 91. | Sustained virological response does not improve long-term glycemic control in patients with type 2 diabetes and chronic hepatitis C |
| |
Li J1, Gordon SC2, Rupp LB3, Zhang T1, Trudeau S1, Holmberg SD4, Moorman AC4, Spradling PR4, Teshale EH4, Boscarino JA5, Schmidt MA6, Daida YG7, Lu M1; CHeCS Investigators. Liver Int. 2018 Dec 20. doi: 10.1111/liv.14031. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 96. | Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective |
| |
Crowley D1,2,3, Van Hout MC4,5, Lambert JS6,7, Kelly E8, Murphy C5,8, Cullen W6. Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 102. | Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C |
| |
D'Ambrosio R1, Pasulo L2, Puoti M3, Vinci M4, Schiavini M5, Lazzaroni S2, Soria A6, Gatti F7, Menzaghi B8, Aghemo A9, Capelli F10, Rumi MG11, Morini L12, Giorgini A13, Pigozzi MG14, Rossini A14, Maggiolo F2, Pan A15, Memoli M16, Spinelli O17, Del Poggio P2, Saladino V18, Spinetti A14, De Bona A13, Capretti A13, Uberti-Foppa C19, Bonfanti P20, Terreni N21, Menozzi F22, Colombo AE17, Giglio O17, Centenaro R23, Borghi M24, Baiguera C3, Picciotto V4, Landonio S5, Gori A25, Magnani C26, Noventa F27, Paolucci S28, Lampertico P24, Fagiuoli S2; NAVIGATORE-Lombardia Study Group. J Hepatol. 2018 Nov 23. pii: S0168-8278(18)32543-1. doi: 10.1016/j.jhep.2018.11.011. [Epub ahead of print] |
|
| |
| 103. | Hepatitis C: is eradication possible? |
| |
Lombardi A1,2, Mondelli MU1,2; ESCMID Study Group for Viral Hepatitis (ESGVH). Liver Int. 2018 Nov 25. doi: 10.1111/liv.14011. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 112. | Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis |
| |
Stone J1, Fraser H2, Lim AG2, Walker JG2, Ward Z2, MacGregor L2, Trickey A2, Abbott S2, Strathdee SA3, Abramovitz D3, Maher L4, Iversen J4, Bruneau J5, Zang G6, Garfein RS3, Yen YF7, Azim T8, Mehta SH9, Milloy MJ10, Hellard ME11, Sacks-Davis R12, Dietze PM13, Aitken C13, Aladashvili M14, Tsertsvadze T15, Mrav?ík V16, Alary M17, Roy E18, Smyrnov P19, Sazonova Y19, Young AM20, Havens JR21, Hope VD22, Desai M23, Heinsbroek E23, Hutchinson SJ24, Palmateer NE24, McAuley A25, Platt L26, Martin NK27, Altice FL28, Hickman M2, Vickerman P2. Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29. |
|
| |
|
|
| |
| 114. | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials |
| |
Grebely J1, Puoti M2, Wedemeyer H3, Cooper C4, Sulkowski MS5, Foster GR6, Berg T7, Villa E8, Rodriguez-Perez F9, Wyles DL10, Schnell G11, Alami NN11, Zhang Z11, Dumas E11, Dore GJ1. Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248. doi: 10.1093/ofid/ofy248. eCollection 2018 Nov. |
|
| |
| 115. | Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C) |
| |
Poordad F1, Shiffman ML2, Ghesquiere W3, Wong A4, Huhn GD5, Wong F6, Ramji A7, Shafran SD8, McPhee F9, Yang R9, Noviello S10, Linaberry M10; ALLY-3C study team. Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print] |
|
| |
| 116. | Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program |
| |
Talal AH1,2, McLeod A2, Andrews P2, Nieves-McGrath H1, Chen Y3, Reynolds A4, Sylvester C2, Dickerson SS5, Markatou M3, Brown LS2. Telemed J E Health. 2018 Oct 16. doi: 10.1089/tmj.2018.0161. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 129. | Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis |
| |
Flamm S1, Mutimer D2, Asatryan A3, Wang S3, Rockstroh J4, Horsmans Y5, Kwo PY6, Weiland O7, Villa E8, Heo J9, Gane E10, Ryder SD11, Welzel TM12, Ruane PJ13, Agarwal K14, Ng TI3, Xue Z3, Lovell SS3, Krishnan P3, Kopecky-Bromberg S3, Trinh R3, Mensa FJ3, Wyles DL15. J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 133. | Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine |
| |
Morey S1,2, Hamoodi A3, Jones D4, Young T1, Thompson C4, Dhuny J5, Buchanan E1, Miller C1, Hewett M1, Valappil M1, Hunter E6, McPherson S1,7. J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017. [Epub ahead of print] |
|
| |
| 134. | Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus |
| |
Saab S1,2,3,4, Ahn T1,2,3,4, McDaniel T1,2,3,4, Yanny B1,2,3,4, Tong MJ1,2,3,4. Gastroenterol Hepatol (N Y). 2018 Aug;14(8):459-462. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 138. | Elimination of Hepatitis C in Liver Transplant Recipients |
| |
Saab S1,2, Challita Y1, Chen PH2, Jimenez MA2, Lee AD2, Saab EG2, Ahn T2, Choi G1,2, Durazo FA1,2, El-Kabany MM1,2, Han SB1,2, Grotts J1, Agopian VG2, Busuttil RW2. J Clin Transl Hepatol. 2018 Sep 28;6(3):247-250. doi: 10.14218/JCTH.2017.00079. Epub 2018 Jun 8. |
|
| |
|
|
| |
| 140. | Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN) |
| |
Minutolo R1, Aghemo A2,3, Chirianni A4, Fabrizi F5, Gesualdo L6, Giannini EG7, Maggi P8, Montinaro V6, Paoletti E9, Persico M10, Perticone F11, Petta S12, Puoti M13, Raimondo G14, Rendina M15, Zignego AL16; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Infection. 2018 Sep 25. doi: 10.1007/s15010-018-1209-2. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 146. | Race and Hepatitis C Care Continuum in an Underserved Birth Cohort |
| |
Kim NJ1,2, Locke CJ1,2, Park H1,2, Magee C2, Bacchetti P3, Khalili M4,5,6. J Gen Intern Med. 2018 Sep 20. doi: 10.1007/s11606-018-4649-6. [Epub ahead of print] |
|
| |
| 147. | Hepatitis C care cascade among persons born 1945-1965: 3 medical centers |
| |
Brady JE1, Vellozzi C, Hariri S, Kruger DL, Nerenz DR, Brown KA, Federman AD, Krauskopf K, Kil N, Massoud OI, Wise JM, Seay TA, Smith BD, Yartel AK, Rein DB. Am J Manag Care. 2018 Sep;24(9):421-427. |
|
| |
|
|
| |
|
|
| |
| 150. | Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance |
| |
Rosenberg BR1,2, Depla M3, Freije CA2, Gaucher D3, Mazouz S3,4, Boisvert M3, Bédard N3, Bruneau J3,5, Rice CM6,7, Shoukry NH3,8. PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep. |
|
| |
| 151. | Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C |
| |
Lynch SM1, Wilson SM2,3, DeRycke EC4, Driscoll MA4,5, Becker WC4,6, Goulet JL4,7, Kerns RD6, Mattocks KM8,9, Brandt CA4,7, Bathulapalli H4, Skanderson M4, Haskell SG4,6, Bastian LA4,6. Pain Med. 2018 Sep 1;19(suppl_1):S5-S11. doi: 10.1093/pm/pny146. |
|
| |
|
|
| |
|
|
| |
| 154. | The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial |
| |
Lawitz E1, Bidair M2, Marbury T3, Jones CT4, Barve A5, Magnusson B6, Barkan DT4, Bodendorf U6, Bracken K7, Canino E4, Chen D4, Dabovic K5, Heimbach T5, Ison M4, Jones CL4, Kovacs SJ7, Lakshman JP5, Li B7, Raman P5, Steiner-Swiat R5, Thohan S7, Wong KA4, Zhong W4, Colvin RA8. Clin Ther. 2018 Sep;40(9):1567-1581.e4. doi: 10.1016/j.clinthera.2018.07.019. Epub 2018 Sep 2. |
|
| |
| 155. | Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
| |
Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Fontana RJ, Gordon SC, Heller T, Holmberg SD, Jhaveri R, Jonas MM, Kiser JJ, Linas BP, Lo Re V 3rd, Morgan TR, Nahass RG, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Swan T, Terrault NA, Trooskin SB, Wong JB, Workowski KA. Clin Infect Dis. 2018 Sep 12. doi: 10.1093/cid/ciy585. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 159. | Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort |
| |
Rossi C1, Butt ZA2, Wong S3, Buxton JA2, Islam N4, Yu A3, Darvishian M2, Gilbert M2, Wong J2, Chapinal N3, Binka M1, Alvarez M3, Tyndall MW2, Krajden M1, Janjua NZ5; BC Hepatitis Testers Cohort Team. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32288-8. doi: 10.1016/j.jhep.2018.07.025. [Epub ahead of print] |
|
| |
|
|
| |
| 161. | A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study |
| |
Evon DM1, Stewart PW2, Amador J2, Serper M3, Lok AS4, Sterling RK5, Sarkar S6, Golin CE7,8, Reeve BB9, Nelson DR10, Reau N11, Lim JK12, Reddy KR3, Di Bisceglie AM13, Fried MW1. PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 165. | Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis Cin Children Ages 6-11 |
| |
Murray KF1, Balistreri WF2, Bansal S3, Whitworth S4, Evans HM5, Gonzalez-Peralta RP6, Wen J7, Massetto B8, Kersey K8, Shao J8, Garrison KL8, Parhy B8, Brainard DM8, Arnon R9, Gillis LA10, Jonas MM11, Chuan-Hao L12, Narkewicz MR13, Schwarz K14, Rosenthal P15. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 177. | Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings |
| |
Scott N1,2, Sacks-Davis R1,2, Pedrana A1,2, Doyle J1,3, Thompson A4,5, Hellard M1,2,3. J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 181. | Changes in Practice and Perception of Hepatitis C and Liver Transplantation: Results of a National Survey |
| |
Shaffer AA1,2, Thomas AG1, Bowring MG1, Van Pilsum Rasmussen SE1, Cash A1, Kucirka L1,2, Alqahtani S3, Gurakar A3, Sulkowski M3,4, Cameron AM1, Segev DL1,2, Durand CM4. Transpl Infect Dis. 2018 Aug 24:e12982. doi: 10.1111/tid.12982. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 187. | Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs |
| |
Grebely J1, Larney S2, Peacock A1, Colledge S1, Leung J3, Hickman M4, Vickerman P4, Blach S5, Cunningham E1, Dumchev K6, Lynskey M7, Stone J4, Trickey A4, Razavi H5, Mattick RP2, Farrell M2, Dore GJ1, Degenhardt L2. Addiction. 2018 Jul 23. doi: 10.1111/add.14393. [Epub ahead of print] |
|
| |
|
|
| |
| 189. | Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection |
| |
Suda G1, Kurosaki M2, Itakura J2, Izumi N2, Uchida Y3, Mochida S3, Hasebe C4, Abe M4, Haga H5, Ueno Y5, Masakane I6, Abe K7, Takahashi A7, Ohira H7, Furuya K8, Baba M8, Yamamoto Y9, Kobayashi T10, Kawakami A11, Kumagai K12, Terasita K1, Ohara M1, Kawagishi N1, Umemura M1, Nakai M1, Sho T1, Natsuizaka M1, Morikawa K1, Ogawa K1, Sakamoto N13; NORTE Study Group. J Gastroenterol. 2018 Jul 17. doi: 10.1007/s00535-018-1495-6. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 193. | Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City |
| |
Tieu HV1,2, Laeyendecker O3,4, Nandi V5, Rose R6, Fernandez R4, Lynch B3, Hoover DR7, Frye V8, Koblin BA1. PLoS One. 2018 Jul 18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 198. | Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection |
| |
Flamm S1, Reddy KR2, Zadeikis N3, Hassanein T4, Bacon BR5, Maieron A6, Zeuzem S7, Bourliere M8, Calleja JL9, Kosloski MP3, Oberoi RK3, Lin CW3, Yu Y3, Lovell S3, Semizarov D3, Mensa FJ3. Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30702-X. doi: 10.1016/j.cgh.2018.07.003. [Epub ahead of print] |
|
| |
|
|
| |
| 200. | Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system |
| |
Sessa M1,2, Bernardi FF1, Vitale A3, Schiavone B3, Gritti G1, Mascolo A1, Bertini M1, Scavone C1, Sportiello L1, Rossi F1, Capuano A1. J Clin Pharm Ther. 2018 Jul 16. doi: 10.1111/jcpt.12744. [Epub ahead of print] |
|
| |
| 201. | Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users |
| |
Major M1, Gutfraind A2,3, Shekhtman L2,4, Cui Q5, Kachko A5, Cotler SJ2, Hajarizadeh B6, Sacks-Davis R7,8, Page K9, Boodram B3, Dahari H10. Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 209. | Incidence and prevalence of antibody to hepatitis C virus in FDNY first responders before and after work at the World Trade Center disaster site |
| |
Webber MP1,2, Liu Y2, Cohen HW1, Schwartz T2, Weiden MD2, Kelly K2, Ortiz V2, Zeig-Owens R1,2, Jaber N2, Colbeth HL2, Prezant DJ2,3. Am J Ind Med. 2018 Jun 20. doi: 10.1002/ajim.22871. [Epub ahead of print] |
|
| |
|
|
| |
| 211. | Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C |
| |
Younossi ZM1,2, Stepanova M3, Reddy R4, Manns MP5, Bourliere M6, Gordon SC7, Schiff E8, Tran T9, Younossi I3, Racila A3. Liver Int. 2018 Jun 12. doi: 10.1111/liv.13900. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 217. | Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1 |
| |
Bourlière M1, Gordon SC2, Schiff ER3, Tran TT4, Ravendhran N5, Landis CS6, Hyland RH7, Stamm LM7, Zhang J7, Dvory-Sobol H7, Subramanian GM7, Brainard DM7, McHutchison JG7, Serfaty L8, Thompson AJ9, Sepe TE10, Curry MP11, Reddy KR12, Manns MP13. Lancet Gastroenterol Hepatol. 2018 May 30. pii: S2468-1253(18)30118-3. doi: 10.1016/S2468-1253(18)30118-3. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 222. | Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005-2015 |
| |
Reilley B1, Leston J2, Doshani M3, Haberling DL4, Persvon M4, Weiser T5, Collier M3, Iralu J6, Mera J7, Haverkate R8. J Community Health. 2018 May 28. doi: 10.1007/s10900-018-0528-7. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 225. | Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis |
| |
Ascione A1, De Luca M2, Melazzini M3, Montilla S3, Trotta MP3, Petta S4, Puoti M5, Sangiovanni V6, Messina V7, Bruno S8, Izzi A9, Villa E10, Aghemo A11, Zignego AL12, Orlandini A13, Fontvanella L14, Gasbarrini A15, Marzioni M16, Giannini EG17, Craxì A4; ABACUS Study Group. Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x. [Epub ahead of print] |
|
| |
|
|
| |
| 227. | Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study |
| |
Butt AA1,2,3,4, Ren Y1, Puenpatom A5, Arduino JM5, Kumar R5, Abou-Samra AB2,3,4. Aliment Pharmacol Ther. 2018 Jul;48(1):35-43. doi: 10.1111/apt.14799. Epub 2018 May 24. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 238. | Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings |
| |
Moorman AC1, Rupp LB2, Gordon SC2, Zhong Y3, Xing J3, Lu M4, Boscarino JA5, Schmidt MA6, Daida YG7, Teshale EH3, Spradling PR3, Holmberg SD3; CHeCS Investigators. Infect Dis Clin North Am. 2018 Jun;32(2):253-268. doi: 10.1016/j.idc.2018.02.002. |
|
| |
| 239. | Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets? |
| |
Ward Z1, Platt L2, Sweeney S2, Hope VD3,4, Maher L5, Hutchinson S6,7, Palmateer N6,7, Smith J8, Craine N8, Taylor A9, Martin N10, Ayres R11, Dillon J12, Hickman M1, Vickerman P1. Addiction. 2018 May 17. doi: 10.1111/add.14217. [Epub ahead of print] |
|
| |
| 240. | Localized US Efforts to Eliminate Hepatitis C |
| |
Gaudino A1, Gay B1, Garmon C2, Selick M3, Vreeland R4, Burk K5, Huriaux E6, Facente SN7, Luetkemeyer A8, Waters P9, Graham CS10. Infect Dis Clin North Am. 2018 Jun;32(2):293-311. doi: 10.1016/j.idc.2018.02.009. |
|
| |
|
|
| |
|
|
| |
| 243. | Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician |
| |
Alroy-Preis S1, Daly ER1, Adamski C1, Dionne-Odom J1,2, Talbot EA1,2, Gao F1, Cavallo SJ1, Hansen K1, Mahoney JC1, Metcalf E1, Loring C1, Bean C1, Drobeniuc J3, Xia GL3, Kamili S3, Montero JT1; New Hampshire and Centers for Disease Control and Prevention Investigation Teams. Clin Infect Dis. 2018 May 14. doi: 10.1093/cid/ciy193. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 246. | Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach |
| |
Deming R1, Ford MM1, Moore MS1, Lim S1, Perumalswami P2, Weiss J3, Wyatt B2, Shukla S4, Litwin A4, Reynoso S4, Laraque F1. J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 256. | Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care |
| |
Martin SA1,2,3, Bosse J4, Wilson A5, Losikoff P6,7, Chiodo L5,4. Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7. |
|
| |
| 257. | Hepatitis C in Pregnancy |
| |
Dibba P1, Cholankeril R2, Li AA3, Patel M4, Fayek M5, Dibble C6, Okpara N7, Hines A8, Ahmed A9. Diseases. 2018 Apr 27;6(2). pii: E31. doi: 10.3390/diseases6020031. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 265. | Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection |
| |
Reau N1, Kwo PY2, Rhee S3, Brown RS Jr.4, Agarwal K5, Angus P6, Gane E7, Kao JH8, Mantry PS9, Mutimer D10, Reddy KR11, Tran TT12, Hu YB3, Gulati A3, Krishnan P3, Dumas EO3, Porcalla A3, Shulman NS3, Liu W3, Samanta S3, Trinh R3, Forns X13. Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046. [Epub ahead of print] |
|
| |
| 266. | Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C |
| |
Wade AJ1,2,3, McCormack A4, Roder C4, McDonald K5, Davies M5,6, Scott N2, Wardrop M1, Athan E1,4, Hellard ME2,3. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910. [Epub ahead of print] |
|
| |
| 267. | Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection |
| |
Martinello M1,2, Bhagani S3, Gane E4, Orkin C5, Cooke G6, Dore GJ1,2, Petoumenos K1, Applegate TL1, Tu E1, Marks P1, Pagani N7, Grebely J1, Nelson M7, Matthews GV1,2. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917. [Epub ahead of print] |
|
| |
| 268. | Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination |
| |
Facente SN1,2, Grebe E3, Burk K4, Morris MD2, Murphy EL2,5, Mirzazadeh A2, Smith AA4, Sanchez MA4, Evans JL2, Nishimura A4, Raymond HF2,6; End Hep C SF. PLoS One. 2018 Apr 11;13(4):e0195575. doi: 10.1371/journal.pone.0195575. eCollection 2018. |
|
| |
|
|
| |
|
|
| |
| 271. | Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era |
| |
Sacks-Davis R1,2, Doyle JS1,3, Rauch A4, Beguelin C4, Pedrana AE1,5, Matthews GV6, Prins M7, van der Valk M8, Klein MB9, Saeed S10, Lacombe K11, Chkhartishvili N12, Altice FL13,14,15, Hellard ME1,5. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051. |
|
| |
|
|
| |
| 273. | HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities |
| |
Bosh KA1, Coyle JR2, Hansen V3, Kim EM3, Speers S4, Comer M5, Maddox LM5, Khuwaja S6, Zhou W6, Jatta A7, Mayer R7, Brantley AD8, Muriithi NW8, Bhattacharjee R9, Flynn C9, Bouton L10, John B10, Keusch J2, Barber CA11, Sweet K11, Ramaswamy C12, Westheimer EF12, VanderBusch L13, Nishimura A14, Vu A14, Hoffman-Arriaga L15, Rowlinson E15, Carter AO16, Yerkes LE16, Li W17, Reuer JR17, Stockman LJ18, Tang T19, Brooks JT1, Teshale EH20, Hall HI1. Epidemiol Infect. 2018 Apr 11:1-11. doi: 10.1017/S0950268818000766. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 277. | Mother-to-child transmission of hepatitis C virus |
| |
Pott H Junior1, Theodoro M2, de Almeida Vespoli J2, Senise JF3, Castelo A3. Eur J Obstet Gynecol Reprod Biol. 2018 Mar 20;224:125-130. doi: 10.1016/j.ejogrb.2018.03.034. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 281. | Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015 |
| |
Kasting ML1,2, Giuliano AR2,3, Reich RR4, Roetzheim RG1,5, Nelson DR6, Shenkman E7,8, Vadaparampil ST9,2. Cancer Epidemiol Biomarkers Prev. 2018 Apr;27(4):503-513. doi: 10.1158/1055-9965.EPI-17-0855. Epub 2018 Mar 27. |
|
| |
|
|
| |
| 283. | Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis |
| |
Wang H1, Swann R2, Thomas E3, Innes HA4,5, Valerio H4,5, Hayes PC6, Allen S7, Barclay ST8, Wilks D9, Fox R10, Bhattacharyya D11, Kennedy N12, Morris J13, Fraser A14, Stanley AJ8, Gunson R15, Mclntyre PG16, Hunt A17, Hutchinson SJ4,5, Mills PR2, Dillon JF18. J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 288. | Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis |
| |
McLinden T1, Moodie EEM1, Hamelin AM1, Harper S1, Rossi C1, Walmsley SL2, Rourke SB3, Cooper C4, Klein MB5, Cox J6. Drug Alcohol Depend. 2018 Feb 20;185:374-380. doi: 10.1016/j.drugalcdep.2017.12.031. [Epub ahead of print] |
|
| |
|
|
| |
| 290. | The Role of Aging, Drug Dependence, and Hepatitis C Comorbidity in Alcoholism Cortical Compromise |
| |
Sullivan EV1, Zahr NM1,2, Sassoon SA2, Thompson WK3, Kwon D1,2, Pohl KM2, Pfefferbaum A1,2. JAMA Psychiatry. 2018 Mar 14. doi: 10.1001/jamapsychiatry.2018.0021. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 297. | Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis CVirus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial |
| |
Durand CM1, Bowring MG1, Brown DM1, Chattergoon MA1, Massaccesi G1, Bair N1, Wesson R1, Reyad A1, Naqvi FF1, Ostrander D1, Sugarman J2, Segev DL1, Sulkowski M1, Desai NM1. Ann Intern Med. 2018 Mar 6. doi: 10.7326/M17-2871. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 300. | Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis |
| |
Petta S1, Adinolfi LE2, Fracanzani AL3, Rini F4, Caldarella R5, Calvaruso V4, Cammà C4, Ciaccio M5, Di Marco V4, Grimaudo S4, Licata A4, Marrone A2, Nevola R2, Pipitone RM4, Pinto A6, Rinaldi L2, Torres D6, Tuttolomondo A6, Valenti L3, Fargion S3, Craxì A4. J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132-6. doi: 10.1016/j.jhep.2018.02.015. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 305. | A Systematic Comparison of African American and Non-African American Patients on Psychosocial Aspects of Hepatitis C Infection |
| |
Sims OT: 1,: 2,: 3,: 4, Hong BA: 5, Ji S: 6, Pollio DE: 7,: 8,: 9, North CS: 10,: 11. J Relig Health. 2018 Feb 6. doi: 10.1007/s10943-018-0565-7. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 308. | Elbasvir/Grazoprevir and Sofosbuvir for HCV Genotype 3 Infection With Compensated Cirrhosis: A Randomized Trial |
| |
Foster GR1, Agarwal K2, Cramp ME3, Moreea S4, Barclay S5, Collier J6, Brown AS7, Ryder SD8, Ustianowski A9, Forton DM10, Fox R11, Gordon F12, Rosenberg WM13, Mutimer DJ14, Du J15, Gilbert CL15, Asante-Appiah E15, Wahl J15, Robertson MN15, Barr E15, Haber B15. Hepatology. 2018 Feb 23. doi: 10.1002/hep.29852. [Epub ahead of print] |
|
| |
| 309. | Efficacy of Elbasvir and Grazoprevir in Participants with Hepatitis C Virus Genotype 4 Infection: A Pooled Analysis |
| |
Asselah T1, Reesink H2, Gerstoft J3, de Ledinghen V4, Pockros PJ5, Robertson M6, Hwang P6, Asante-Appiah E6, Wahl J6, Nguyen BY6, Barr E6, Talwani R6, Serfaty L7. Liver Int. 2018 Feb 20. doi: 10.1111/liv.13727. [Epub ahead of print] |
|
| |
| 310. | Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia: a multicentre open-label study |
| |
Mazzaro C1, Dal Maso L2, Quartuccio L3, Ghersetti M4, Lenzi M5, Mauro E4, Bond M3, Casarin P4, Gattei V6, Crosato IM7, De Vita S3, Pozzato G8. Clin Exp Rheumatol. 2018 Feb 13. [Epub ahead of print] |
|
| |
|
|
| |
| 312. | Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies |
| |
Grebely J1, Feld JJ2, Wyles D3, Sulkowski M4, Ni L5, Llewellyn J5, Mir HM5, Sajed N5, Stamm LM5, Hyland RH5, McNally J5, Brainard DM5, Jacobson I6, Zeuzem S7, Bourlière M8, Foster G9, Afdhal N10, Dore GJ1. Open Forum Infect Dis. 2018 Feb 9;5(2):ofy001. doi: 10.1093/ofid/ofy001. eCollection 2018 Feb. |
|
| |
| 313. | Epidemiology and risk factors for hepatitis C virus infection in a high-prevalence population |
| |
Fill MA1, Sizemore LA2, Rickles M2, Cooper KC3, Buecker CM4, Mullins HL5, Hofmeister MG1, Abara WE1, Foster MA6, Asher AK6, Schaffner W7, Dunn JR2, Jones TF2, Wester C2. Epidemiol Infect. 2018 Feb 12:1-7. doi: 10.1017/S0950268818000080. [Epub ahead of print] |
|
| |
|
|
| |
| 315. | Capacity of non-invasive hepatic fibrosis algorithms to replace transient elastography to exclude cirrhosis in people with hepatitis C virus infection: A multi-centre observational study |
| |
Kelly ML1,2,3, Riordan SM4,5, Bopage R2, Lloyd AR1,3,6, Post JJ1,2,3,4. PLoS One. 2018 Feb 13;13(2):e0192763. doi: 10.1371/journal.pone.0192763. eCollection 2018. |
|
| |
|
|
| |
| 317. | The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities |
| |
Cortesi PA1, Belli LS2,3, Facchetti R1, Mazzarelli C2, Perricone G2, De Nicola S2, Cesana G1, Duvoux C4, Mantovani LG1,3, Strazzabosco M3,5; European Liver and Intestine Transplant Association (ELITA). J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 321. | Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA |
| |
Chhatwal J1,2,3, Chen Q1,2, Ayer T4, Bethea ED1,2,3, Kanwal F5,6, Kowdley KV7, Wang X8, Roberts MS9, Gordon SC10. Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14527. [Epub ahead of print] |
|
| |
|
|
| |
| 323. | Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis Cinfection |
| |
Reau N1, Robertson MN2, Feng HP2, Caro L2, Yeh WW2, Nguyen BT2, Wahl J2, Barr E2, Hwang P2, Klopfer SO2. Hepatol Commun. 2017 Aug 22;1(8):757-764. doi: 10.1002/hep4.1081. eCollection 2017 Oct. |
|
| |
|
|
| |
|
|
| |
| 326. | Vertical transmission of hepatitis C: Testing and health-care engagement |
| |
Reid S1,2, Day CA3, Bowen DG4, Minnis J2, Ludlow J5,6, Jacobs S5,6, Gordon A5,6, Haber PS2,3. J Paediatr Child Health. 2018 Jan 2. doi: 10.1111/jpc.13832. [Epub ahead of print] |
|
| |
|
|
| |
| 328. | Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection |
| |
Collins LF1, Chan A2, Zheng J3, Chow SC3,4, Wilder JM4,5, Muir AJ4,5, Naggie S2,4. Open Forum Infect Dis. 2017 Dec 9;5(1):ofx264. doi: 10.1093/ofid/ofx264. eCollection 2018 Jan. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 332. | Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition |
| |
Indolfi G1, Hierro L2, Dezsofi A3, Jahnel J4, Debray D5, Hadzic N6, Czubowski P7, Gupte G8, Mozer-Glassberg Y9, van der Woerd W10, Smets F11, Verkade HJ12, Fischler B12,13. J Pediatr Gastroenterol Nutr. 2017 Dec 28. doi: 10.1097/MPG.0000000000001872. [Epub ahead of print] |
|
| |
| 333. | Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis |
| |
McDonald SA1,2, Innes HA1,2, Aspinall EJ1,2, Hayes PC3, Alavi M2, Valerio H1,2, Goldberg DJ1,2, Hutchinson SJ1,2. Liver Int. 2017 Dec 30. doi: 10.1111/liv.13681. [Epub ahead of print] |
|
| |
|
|
| |
| 335. | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection |
| |
Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group N Engl J Med 2014; 370:211-221January 16, 2014DOI: 10.1056/NEJMoa1306218 |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 339. | Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes |
| |
Younossi ZM1,2, Stepanova M3, Asselah T4, Foster G5, Patel K6, Brau N7, Swain M8, Tran T9, Esteban R10, Colombo M11, Pianko S12, Henry L3, Bourliere M13. Clin Infect Dis. 2017 Dec 20. doi: 10.1093/cid/cix1106. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 344. | GHOST: global hepatitis outbreak and surveillance technology |
| |
Longmire AG1,2, Sims S1,3,2, Rytsareva I1, Campo DS4, Skums P1,3, Dimitrova Z1, Ramachandran S1, Medrzycki M1, Thai H1, Ganova-Raeva L1, Lin Y1, Punkova LT1, Sue A1, Mirabito M5,2, Wang S5,2, Tracy R5,2, Bolet V6, Sukalac T5, Lynberg C7, Khudyakov Y1. BMC Genomics. 2017 Dec 6;18(Suppl 10):916. doi: 10.1186/s12864-017-4268-3. |
|
| |
| 345. | Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment |
| |
Marshall WL1, Feng HP2, Wenning L1, Garrett G1, Huang X1, Liu F1, Panebianco D1, Caro L1, Fandozzi C1, Lasseter KC3, Preston RA4, Marbury T5, Butterton JR1, Iwamoto M1, Yeh WW1. Eur J Drug Metab Pharmacokinet. 2017 Dec 15. doi: 10.1007/s13318-017-0451-9. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 350. | Hepatitis C virus genotyping of organ donor samples to aid in transplantation of HCV-positive organs |
| |
Gentile C1, Van Deerlin VM1, Goldberg DS2,3,4, Reese PP3,4,5, Hasz RD6, Abt P7, Blumberg E8, Farooqi MS9. Clin Transplant. 2017 Dec 8. doi: 10.1111/ctr.13172. [Epub ahead of print] |
|
| |
| 351. | Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study) |
| |
Rosenthal E1, Fougerou-Leurent C2,3, Renault A3,4, Carrieri MP5,6, Marcellin F5,6, Garraffo R7, Teicher E8, Aumaitre H9, Lacombe K10, Bailly F11, Billaud E12, Chevaliez S13, Dominguez S14, Valantin MA15, Reynes J16, Naqvi A17, Cotte L18, Metivier S19, Leroy V20, Dupon M21, Allegre T22, De Truchis P23, Jeantils V24, Chas J25, Salmon-Ceron D26, Morlat P27, Neau D28, Perré P29, Piroth L30, Pol S31, Bourlière M32, Pageaux GP33, Alric L34, Zucman D35, Girard PM10, Poizot-Martin I36,37, Yazdanpanah Y38, Raffi F12, Pabic EL2,3, Tual C2,3, Pailhé A39, Amri I39, Bellissant E2,3,4, Molina JM40; ANRS HC31 SOFTRIH Study Group. Collaborators (17) HIV Med. 2017 Dec 7. doi: 10.1111/hiv.12571. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 354. | Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ? 15) |
| |
McCaughan GW1, Thwaites PA2, Roberts SK3, Strasser SI1, Mitchell J3, Morales B2, Mason S1, Gow P2, Wigg A4, Tallis C5, Jeffrey G6, George J7, Thompson AJ8, Parker FC2, Angus PW2; Australian Liver Association Clinical Research Network. Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14404. [Epub ahead of print] |
|
| |
| 355. | The Effect of Interferon-Free Regimens on Health-Related Quality of Life in East Asian Patients with Chronic Hepatitis C |
| |
Younossi ZM1,2, Stepanova M3, Henry L3, Han KH4, Ahn SH4, Lim YS5, Chuang WL6, Kao JH7, Kinh N8, Lai CL9, Yuen MF9, Chan HL10, Lai W11. Liver Int. 2017 Dec 2. doi: 10.1111/liv.13650. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 358. | Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3 |
| |
Younossi ZM1, Stepanova M2, Jacobson IM3, Asselah T4, Gane EJ5, Lawitz E6, Foster GR7, Roberts SK8, Thompson AJ8, Willems BE9, Welzel TM10, Pearlman B11, Younossi I2, Racila A1, Henry L2. Aliment Pharmacol Ther. 2018 Jan;47(2):259-267. doi: 10.1111/apt.14423. Epub 2017 Nov 27. |
|
| |
|
|
| |
|
|
| |
| 361. | Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals |
| |
Zhu J, Hazen RJ, Joyce C, Delpino A, Kirkham HS, Strickland CD, Markes-Wilson S, Kim T, Kang M, Rubin RA, Stein LL.AbstractJ Am Pharm Assoc (2003). 2017 Nov 16. pii: S1544-3191(17)30967-6. doi: 10.1016/j.japh.2017.10.011. [Epub ahead of print] |
|
| |
|
|
| |
| 363. | Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir |
| |
Younossi ZM1, Stepanova M2, Gordon S3, Zeuzem S4, Mann MP5, Jacobson I6, Bourliere M7, Cooper C8, Flamm S9, Reddy KR10, Kowdley K11, Younossi I2, Hunt S2. Clin Gastroenterol Hepatol. 2017 Nov 16. pii: S1542-3565(17)31360-5. doi: 10.1016/j.cgh.2017.11.023. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 368. | Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems |
| |
Camus G1, Xu S2, Han B2, Lu J2, Dvory-Sobol H2, Yu M2, Cheng G2, Miller MD2, Doehle BP2, Mo H2. Virology. 2017 Nov 22;514:134-141. doi: 10.1016/j.virol.2017.11.003. [Epub ahead of print] |
|
| |
| 369. | Improving patient access to hepatitis C virus treatment |
| |
McLaughlin MM, Marx KT, Terriff C; American Academy of HIV Medicine Pharmacists Committee. AbstractJ Am Pharm Assoc (2003). 2017 Nov 16. pii: S1544-3191(17)30969-X. doi: 10.1016/j.japh.2017.10.013. [Epub ahead of print] |
|
| |
| 370. | No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV |
| |
Chaudhury CS1, Sheehan J1, Chairez C1, Akoth E2, Gross C2, Silk R2, Kattakuzhy S2, Rosenthal E2, Kottilil S2, Masur H3, Hadigan C1. J Infect Dis. 2017 Nov 17. doi: 10.1093/infdis/jix517. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 373. | Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1 or 4 and Prior Direct-acting Antiviral Treatment Failure |
| |
Poordad F1, Pol S2, Asatryan A3, Buti M4, Shaw D5, Hézode C6, Felizarta F7, Reindollar RW8, Gordon SC9, Pianko S10, Fried MW11, Bernstein DE12, Gallant J13, Lin CW3, Lei Y3, Ng TI3, Krishnan P3, Kopecky-Bromberg S3, Kort J3, Mensa F3. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29671. [Epub ahead of print] |
|
| |
|
|
| |
| 375. | Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study |
| |
Brown A1, Hézode C2, Zuckerman E3, Foster GR4, Zekry A5, Roberts SK6, Lahser F7, Durkan C7, Badshah C7, Zhang B7, Robertson M7, Wahl J7, Barr E7, Haber B7; C-SCAPE Study Investigators. J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801. [Epub ahead of print] |
|
| |
| 376. | Assessing risk of fibrosis progression and liver-related clinical outcomes among patients with both early stage and advanced chronic hepatitis C |
| |
Konerman MA1, Lu D1, Zhang Y1, Thomson M1, Zhu J1, Verma A2, Liu B1, Talaat N1, Balis U3, Higgins PDR1, Lok ASF1, Waljee AK1,4. PLoS One. 2017 Nov 6;12(11):e0187344. doi: 10.1371/journal.pone.0187344. eCollection 2017. |
|
| |
| 377. | Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world |
| |
Tempestilli M1, Fabbri G2, Mastrorosa I2, Timelli L2, Notari S1, Bellagamba R2, Libertone R2, Lupi F2, Zaccarelli M2, Antinori A2, Agrati C1, Ammassari A2. J Antimicrob Chemother. 2017 Nov 2. doi: 10.1093/jac/dkx348. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 381. | Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe |
| |
Fraser H1, Martin NK2, Brummer-Korvenkontio H3, Carrieri P4, Dalgard O5, Dillon J6, Goldberg D7, Hutchinson S8, Jauffret-Roustide M9, Kåberg M10, Matser AA11, Mati?i? M12, Midgard H13, Mravcik V14, Øvrehus A15, Prins M16, Reimer J17, Robaeys G18, Schulte B19, van Santen DK20, Zimmermann R21, Vickerman P22, Hickman M22. J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387-5. doi: 10.1016/j.jhep.2017.10.010. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 386. | Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV) |
| |
Brown AN1, Liu L2, Rodriquez JL3, Zhao L2, Schuster L2, Li E2, Wang GP2,4, Neely MN5, Yamada W5, Drusano GL3. Sci Rep. 2017 Oct 31;7(1):14421. doi: 10.1038/s41598-017-15007-2. |
|
| |
|
|
| |
| 388. | Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review |
| |
Larney S1, Peacock A2, Leung J3, Colledge S2, Hickman M4, Vickerman P4, Grebely J5, Dumchev KV6, Griffiths P7, Hines L8, Cunningham EB5, Mattick RP2, Lynskey M8, Marsden J8, Strang J8, Degenhardt L2. Lancet Glob Health. 2017 Dec;5(12):e1208-e1220. doi: 10.1016/S2214-109X(17)30373-X. Epub 2017 Oct 23. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 394. | Should we treat acute hepatitis C? A decision and cost-effectiveness analysis |
| |
Bethea E1,2,3, Chen Q1,2, Hur C1,2,3, Chung RT2,3, Chhatwal J1,2,3. Hepatology. 2017 Oct 23. doi: 10.1002/hep.29611. [Epub ahead of print] |
|
| |
|
|
| |
| 396. | Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women |
| |
Sarkar M1, Dodge JL2, Greenblatt RM3, Kuniholm MH4, DeHovitz J5, Plankey M6, Kovacs A7, French AL8, Seaberg EC9, Ofotokun I10, Fischl M11, Overton E12, Kelly E13, Bacchetti P14, Peters MG1; Women?s Interagency HIV Study. Clin Infect Dis. 2017 Jul 26. doi: 10.1093/cid/cix643. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 401. | Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-naïve Hepatitis C virus Genotype 1-infected Patients without Cirrhosis Treated with a Simeprevir/Sofosbuvir/Ledipasvir Regimen |
| |
Bourgeois S1, Horsmans Y2, Nevens F3, van Vlierberghe H4, Moreno C5, Beumont M6, Vijgen L6, van Eygen V6, Luo D7, Hillewaert V6, Van Remoortere P7, van de Logt J8, Ouwerkerk-Mahadevan S6. Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01217-17. doi: 10.1128/AAC.01217-17. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 405. | Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies |
| |
Origa R1, Ponti ML2, Filosa A3, Galeota Lanza A3, Piga A4, Saracco GM4, Pinto V5, Picciotto A6, Rigano P7, Madonia S7, Rosso R8, D'Ascola D9, Cappellini MD10, D'Ambrosio R10, Tartaglione I11, De Franceschi L12, Gianesin B5, Di Marco V13, Forni GL5; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24911. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 414. | Hepatitis C Virus Prevalence in Egyptian Americans in Southern California |
| |
Saab S1, Viramontes MR, Chalifoux SL, Craw CJ, Ramirez SD, Bau SN, Arevalo DG, Saab EG, Saab CE, Craw CS, Estafanous A, Messiah R, Messiah W, El Kabany M. J Clin Gastroenterol. 2017 Jun 14. doi: 10.1097/MCG.0000000000000858. [Epub ahead of print] |
|
| |
|
|
| |
| 416. | The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience |
| |
Martini S1, Donato MF2, Mazzarelli C3, Rendina M4, Visco-Comandini U5, Filì D6, Gianstefani A7, Fagiuoli S8, Melazzini M9, Montilla S9, Pani L9, Petraglia S9, Russo P9, Trotta MP9, Carrai P10, Caraceni P7; ITACOPS study group. Liver Int. 2017 Sep 16. doi: 10.1111/liv.13588. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 421. | Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model |
| |
Wright N1, Reimer J, Somaini L, Roncero C, Maremmani I, Simon N, Krajci P, Littlewood R, D'Agnone O, Alho H, Rolland B. Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962. [Epub ahead of print] |
|
| |
| 422. | Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial |
| |
Wyles D1, Poordad F2, Wang S3, Alric L4, Felizarta F5, Kwo PY6, Maliakkal B7, Agarwal K8, Hassanein T9, Weilert F10, Lee SS11, Kort J3, Lovell SS3, Liu R3, Lin CW3, Pilot-Matias T3, Krishnan P3, Mensa FJ3. Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 426. | Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis |
| |
Platt L1, Minozzi S2, Reed J3, Vickerman P4, Hagan H3, French C4, Jordan A3, Degenhardt L5, Hope V6, Hutchinson S7, Maher L8, Palmateer N7, Taylor A9, Bruneau J10, Hickman M4. Addiction. 2017 Sep 11. doi: 10.1111/add.14012. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 429. | A Randomized Trial of Off-Site Collaborative Care for Depression in Chronic Hepatitis C Virus |
| |
Kanwal F1, Pyne JM2,3, Tavakoli-Tabasi S4, Nicholson S5, Dieckgraefe B6, Storay E7, Goetz MB8, Kramer JR9, Smith D10, Sansgiry S11, Tansel A12, Gifford AL13,14, Asch SM15. Health Serv Res. 2017 Sep 11. doi: 10.1111/1475-6773.12758. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 433. | Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s |
| |
Garvey P1, Murphy N2, Flanagan P2, Brennan A2, Courtney G3, Crosbie O4, Crowe J5, Hegarty J6, Lee J7, McIver M2, McNulty C6, Murray F8, Nolan N6, O'Farrelly C9, Stewart S5, Tait M10, Norris S11, Thornton L2. J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249-3. doi: 10.1016/j.jhep.2017.07.034. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 445. | Chronic hepatitis C virus infection and neurocognitive function in adult survivors of childhood cancer |
| |
Studaway A1, Ojha RP2, Brinkman TM1,3, Zhang N4, Baassiri M5, Banerjee P1, Ehrhardt MJ1,5, Srivastava D4, Robison LL1, Hudson MM1,5, Krull KR1,3. Cancer. 2017 Jul 25. doi: 10.1002/cncr.30913. [Epub ahead of print] |
|
| |
| 446. | Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study |
| |
Wiessing L1, Ferri M2, B?lá?ková V3,4,5, Carrieri P6,7, Friedman SR8, Folch C9,10, Dolan K11, Galvin B12, Vickerman P13, Lazarus JV14,15, Mrav?ík V3,4,16, Kretzschmar M17,18, Sypsa V19, Sarasa-Renedo A10,20, Uusküla A21, Paraskevis D19, Mendão L22, Rossi D23, van Gelder N2, Mitcheson L24, Paoli L25,26, Gomez CD27, Milhet M27, Dascalu N28, Knight J29, Hay G30, Kalamara E2, Simon R2; EUBEST working group, Comiskey C31, Rossi C32, Griffiths P2. Harm Reduct J. 2017 Apr 22;14(1):19. doi: 10.1186/s12954-017-0141-6. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 451. | The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease |
| |
Young J1, Weis N2, Hofer H3, Irving W4, Weiland O5, Giostra E6, Pascasio JM7, Castells L8, Prieto M9, Postema R10, Lefevre C11, Evans D11, Bucher HC12, Calleja JL13. BMC Infect Dis. 2017 Jan 7;17(1):45. doi: 10.1186/s12879-016-2106-x. |
|
| |
| 452. | Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial |
| |
van der Ree MH1, de Vree JM2, Stelma F1, Willemse S3, van der Valk M4, Rietdijk S5, Molenkamp R6, Schinkel J6, van Nuenen AC7, Beuers U3, Hadi S8, Harbers M8, van der Veer E9, Liu K10, Grundy J10, Patick AK10, Pavlicek A10, Blem J10, Huang M10, Grint P10, Neben S10, Gibson NW10, Kootstra NA7, Reesink HW11. Lancet. 2017 Jan 10. pii: S0140-6736(16)31715-9. doi: 10.1016/S0140-6736(16)31715-9. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 455. | Frequency of and Factors Associated with Receipt of Liver-Related Specialty Care Among Patients with Hepatitis C in the Chronic Hepatitis Cohort Study |
| |
Foster MA1, Xing J2, Moorman AC2, Boscarino J3, Gordon SC4, Lu M4, Rupp L4, Schmidt MA5, Trinacty CM6, Xu F2, Holmberg SD2, Spradling PR2. Dig Dis Sci. 2016 Aug 10. [Epub ahead of print] |
|
| |
| 456. | Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras |
| |
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V 3rd, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R; North American AIDS Cohort Collaboration on Research and Design of IeDEA; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Clin Infect Dis. 2016 Aug 9. pii: ciw531. [Epub ahead of print] |
|
| |
| 457. | Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening |
| |
Irvin R1, McAdams-Mahmoud A1, Hickman D2, Wilson J2, Fenwick W2, Chen I3, Irvin N4, Falade-Nwulia O1, Sulkowski M1, Chaisson R1, Thomas DL1, Mehta SH5. J Community Med Health Educ. 2016 Jun;6(3). pii: 431. Epub 2016 May 30. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 469. | Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort |
| |
Foster GR1, Coppola C2, Derbala M3, Ferenci P4, Orlandini A5, Reddy KR6, Tallarico L7, Shiffman ML8, Ahlers S9, Bakalos G10, Hassanein T11; GUARD-C Study Group. PLoS One. 2016 Mar 28;11(3):e0151703. doi: 10.1371/journal.pone.0151703. eCollection 2016. |
|
| |
|
|
| |
| 471. | GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study |
| |
Rodriguez-Torres M1, Glass S2, Hill J3, Freilich B4, Hassman D5, Di Bisceglie AM6, Taylor JG7, Kirby BJ7, Dvory-Sobol H7, Yang JC7, An D7, Stamm LM7, Brainard DM7, Kim S8, Krefetz D9, Smith W10, Marbury T11, Lawitz E12. J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527. [Epub ahead of print] |
|
| |
|
|
| |
| 473. | Hepatitis C Disease Burden in the United States in the Era of Oral Direct-Acting Antivirals |
| |
Chhatwal J1,2,3, Wang X4,5, Ayer T4, Kabiri M6, Chung RT2,3, Hur C1,2,3, Donohue JM6, Roberts MS6, Kanwal F7,8. Hepatology. 2016 Mar 25. doi: 10.1002/hep.28571. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 479. | Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies |
| |
Martinello M1, Hellard M, Shaw D, Petoumenos K, Applegate T, Grebely J, Yeung B, Maire L, Iser D, Lloyd A, Thompson A, Sasadeusz J, Haber P, Dore GJ, Matthews GV. Antivir Ther. 2016 Feb 11. doi: 10.3851/IMP3035. [Epub ahead of print] |
|
| |
|
|
| |
| 481. | Is increased HCV case-finding combined with current or 8-12 week DAA therapy cost-effective in UK prisons? A prevention benefit analysis |
| |
Martin NK1,2, Vickerman P2, Brew IF3, Williamson J3, Miners A4, Irving WL5, Saksena S6, Hutchinson SJ7, Mandal S8, O'Moore E8, Hickman M2. Hepatology. 2016 Feb 10. doi: 10.1002/hep.28497. [Epub ahead of print] |
|
| |
|
|
| |
| 483. | Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C |
| |
Valcour VG1, Rubin LH, Obasi MU, Maki PM, Peters MG, Levin S, Crystal HA, Young MA, Mack WJ, Cohen MH, Pierce CB, Adimora AA, Tien PC; Women?s Interagency HIV Study protocol team. J Acquir Immune Defic Syndr. 2016 Feb 16. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 490. | Synergistic activity of combined NS5A inhibitors |
| |
O'Boyle DR 2nd1, Nower PT2, Gao M2, Fridell R2, Wang C2, Hewawasam P2, Lopez O2, Tu Y2, Meanwell NA2, Belema M2, Roberts SB2, Cockett M2, Sun JH2. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02639-15. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 493. | Potent Antiviral Activity of Direct-Acting Antivirals, ABT-493 and ABT-530, With 3-day Monotherapy for Hepatitis C Genotype 1 Infection |
| |
Lawitz EJ1, O'Riordan WD2, Asatryan A3, Freilich BL4, Box TD5, Overcash JS2, Lovell S3, Ng TI3, Liu W3, Campbell A3, Lin CW3, Yao B3, Kort J3. Antimicrob Agents Chemother. 2015 Dec 28. pii: AAC.02264-15. [Epub ahead of print] |
|
| |
|
|
| |
| 495. | Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial |
| |
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK. Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10. |
|
| |
|
|
| |
|
|
| |
| 498. | Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers |
| |
Patel K1,2,3, Tillmann HL1,2, Matta B2, Sheridan MJ4, Gardner SD5, Shackel NA3, McHutchison JG6, Goodman ZD7. Aliment Pharmacol Ther. 2015 Nov 11. doi: 10.1111/apt.13471. [Epub ahead of print] |
|
| |
|
|
| |
| 500. | Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET |
| |
Brown RS Jr1, O'Leary JG2, Reddy KR3, Kuo A4, Morelli GJ5, Burton JR Jr6, Stravitz RT7, Durand C8, Di Bisceglie AM9, Kwo P10, Frenette CT11, Stewart TG12, Nelson DR5, Fried MW12, Terrault NA13; HCV-TARGET Study Group. Liver Transpl. 2015 Oct 31. doi: 10.1002/lt.24366. [Epub ahead of print] |
|
| |
|
|
| |
| 502. | Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study |
| |
Jensen DM1, Brunda M2, Elston R3, Gane EJ4, George J5, Glavini K6, Hammond JM6, Le Pogam S7, Nájera I6, Passe S2, Piekarska A8, Rodriguez I2, Zeuzem S9, Chu T2; ANNAPURNA study investigators. Liver Int. 2015 Oct 31. doi: 10.1111/liv.12997. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 509. | Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE |
| |
Buti M1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Forns X8. Clin Infect Dis. 2015 Sep 14. pii: civ722. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 516. | The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial) |
| |
Poordad F1, Rustgi V2, Brown RS Jr3, Patel V4, Kugelmas M5, Regenstein F6, Balart L7, LaBrecque D8, Brown K9, Avila M10, Biederman M11, Freed G12, Smith R13, Bernstein M14, Arnold H15, Cahan J16, Fink S17, Katkov W18, Massoumi H19, Harrison S20. Therap Adv Gastroenterol. 2015 Sep;8(5):263-9. doi: 10.1177/1756283X15588876. |
|
| |
|
|
| |
|
|
| |
| 519. | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV |
| |
Susanna Naggie, M.D., M.H.S., Curtis Cooper, M.D., Michael Saag, M.D., Kimberly Workowski, M.D., Peter Ruane, M.D., William J. Towner, M.D., Kristen Marks, M.D., Anne Luetkemeyer, M.D., Rachel P. Baden, M.D., Paul E. Sax, M.D., Edward Gane, M.D., Jorge Santana-Bagur, M.D., Luisa M. Stamm, M.D., Ph.D., Jenny C. Yang, Pharm.D., Polina German, Pharm.D., Hadas Dvory-Sobol, Ph.D., Liyun Ni, M.A., Phillip S. Pang, M.D., Ph.D., John G. McHutchison, M.D., Catherine A.M. Stedman, M.B., Ch.B., Ph.D., Javier O. Morales-Ramirez, M.D., Norbert Bräu, M.D., Dushyantha Jayaweera, M.D., Amy E. Colson, M.D., Pablo Tebas, M.D., David K. Wong, M.D., Douglas Dieterich, M.D., and Mark Sulkowski, M.D. for the ION-4 Investigators |
|
| |
|
|
| |
| 521. | Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 |
| |
David L. Wyles, M.D., Peter J. Ruane, M.D., Mark S. Sulkowski, M.D., Douglas Dieterich, M.D., Anne Luetkemeyer, M.D., Timothy R. Morgan, M.D., Kenneth E. Sherman, M.D., Ph.D., Robin Dretler, M.D., Dawn Fishbein, M.D., Joseph C. Gathe, Jr., M.D., Sarah Henn, M.D., Federico Hinestrosa, M.D., Charles Huynh, D.O., Cheryl McDonald, M.D., Anthony Mills, M.D., Edgar Turner Overton, M.D., Moti Ramgopal, M.D., Bruce Rashbaum, M.D., Graham Ray, M.S.N., A.N.P., Anthony Scarsella, M.D., Joseph Yozviak, D.O., Fiona McPhee, Ph.D., Zhaohui Liu, Ph.D., Eric Hughes, M.D., Ph.D., Philip D. Yin, M.D., Ph.D., Stephanie Noviello, M.D., and Peter Ackerman, M.D. for the ALLY-2 Investigators |
|
| |
|
|
| |
| 523. | Prevalence of Cirrhosis in Hepatitis C Patients in the Chronic Hepatitis Cohort Study (CHeCS): A Retrospective and Prospective Observational Study |
| |
Gordon SC1, Lamerato LE2, Rupp LB3, Holmberg SD4, Moorman AC4, Spradling PR4, Teshale E4, Xu F4, Boscarino JA5, Vijayadeva V6, Schmidt MA7, Oja-Tebbe N2, Lu M2. Am J Gastroenterol. 2015 Aug;110(8):1169-77. doi: 10.1038/ajg.2015.203. Epub 2015 Jul 28. |
|
| |
|
|
| |
|
|
| |
| 526. | Development of sofosbuvir for the treatment of hepatitis C virus infection |
| |
Lawitz E1, Jacobson IM2, Nelson DR3, Zeuzem S4, Sulkowski MS5, Esteban R6, Brainard D7, McNally J7, Symonds WT7, McHutchison JG7, Dieterich D8, Gane E9. Ann N Y Acad Sci. 2015 Jul 31. doi: 10.1111/nyas.12832. [Epub ahead of print] |
|
| |
|
|
| |
| 528. | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) |
| |
Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4. |
|
| |
| 529. | Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial |
| |
Shiffman ML1, Cheinquer H2, Berg CP3, Berg T4, de Figueiredo-Mendes C5, Dore GJ6, Ferraz ML7, Mendes-Corrêa MC8, Lima MP9, Parise ER10, Rios AM11, Reuter T12, Sanyal AJ13, Shafran SD14, Hohmann M15, Tatsch F16,17, Bakalos G18, Zeuzem S1 Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24. |
|
| |
| 530. | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 |
| |
Naggie S1, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, Gane E, Santana-Bagur J, Stamm LM, Yang JC, German P, Dvory-Sobol H, Ni L, Pang PS, McHutchison JG, Stedman CA, Morales-Ramirez JO, Bräu N, Jayaweera D, Colson AE, Tebas P, Wong DK, Dieterich D, Sulkowski M; ION-4 Investigators. N Engl J Med. 2015 Aug 20;373(8):705-13. doi: 10.1056/NEJMoa1501315. Epub 2015 Jul 21. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 535. | Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis |
| |
Lawitz E1, Makara M2, Akarca US3, Thuluvath PJ4, Preotescu LL5, Varunok P6, Morillas RM7, Hall C8, Mobashery N8, Redman R8, Pilot-Matias T8, Vilchez RA8, Hézode C9. Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936-1. doi: 10.1053/j.gastro.2015.07.001. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 539. | Treating Fibrosing Cholestatic Hepatitis C with Sofosbuvir and Ribavirin: A Matched Analysis |
| |
Saab S1,2, Jimenez M3, Bau S2, Goo T1, Zhao D3, Durazo F1,2, Han S1,2, El Kabany M1,2, Kaldas F2, Tong MJ2,4, Busuttil RW2. Clin Transplant. 2015 Jul 4. doi: 10.1111/ctr.12584. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 545. | The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study |
| |
Fortier E1, Alavi M2, Micallef M2, Dunlop AJ3, Balcomb AC4, Day CA5, Treloar C6, Bath N7, Haber PS8, Dore GJ2, Bruneau J9, Grebely J10; ETHOS Study Group. Int J Drug Policy. 2015 Jun 11. pii: S0955-3959(15)00181-4. doi: 10.1016/j.drugpo.2015.06.001. [Epub ahead of print] |
|
| |
| 546. | A phase II, randomized, controlled trial of S-adenosylmethionine in reducing serum alpha-fetoprotein (AFP) in patients with hepatitis C cirrhosis and elevated AFP |
| |
Morgan TR1, Osann K2, Bottiglieri T3, Pimstone N4, Hoefs JC5, Hu KQ6, Hassanein T7, Boyer T8, Kong L9, Chen WP10, Richmond E11, Gonzalez R12, Rodriguez LM13, Meyskens FL14. Cancer Prev Res (Phila). 2015 Jun 30. pii: canprevres.0029.2015. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 550. | Underascertainment of Acute Hepatitis C Virus Infections in the U.S. Surveillance System: A Case Series and Chart Review |
| |
Onofrey S, Aneja J, Haney GA, Nagami EH, Jr AD, Lauer GM, Hills-Evans K, Barton K, Kulaga S, Bowen MJ, Cocoros N, McGovern BH, Church DR, Kim AY. Ann Intern Med. 2015 Jun 30. doi: 10.7326/M14-2939. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 557. | Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent |
| |
Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print] |
|
| |
|
|
| |
| 559. | Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study |
| |
Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 568. | Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013 |
| |
Wandeler G1, Schlauri M2, Jaquier ME2, Rohrbach J2, Metzner KJ3, Fehr J3, Ambrosioni J4, Cavassini M5, Stöckle M6, Schmid P7, Bernasconi E8, Keiser O9, Salazar-Vizcaya L9, Furrer H2, Rauch A2; Swiss HIV Cohort Study, Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. Open Forum Infect Dis. 2015 Mar 25;2(1):ofv026. doi: 10.1093/ofid/ofv026. eCollection |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 581. | Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin |
| |
Rower JE1, Meissner EG2, Jimmerson LC1, Osinusi A3, Sims Z2, Petersen T2, Bushman LR1, Wolfe P4, McHutchison JG5, Kottilil S2, Kiser JJ6. J Antimicrob Chemother. 2015 May 13. pii: dkv122. [Epub ahead of print] |
|
| |
| 582. | Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study |
| |
Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill J, Hull M, Walmsley S, Klein MB. HIV Clin Trials. 2015 May-Jun;16(3):100-10. doi: 10.1179/501100000024. Epub 2015 May 14. |
|
| |
|
|
| |
| 584. | Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease |
| |
Charlton M1, Everson GT2, Flamm SL3, Kumar P4, Landis C5, Brown RS Jr6, Fried MW7, Terrault NA8, O'Leary JG9, Vargas HE10, Kuo A11, Schiff E12, Sulkowski MS13, Gilroy R14, Watt KD15, Brown K16, Kwo P17, Pungpapong S18, Korenblat KM19, Muir AJ20, Teperman L21, Fontana RJ22, Denning J23, Arterburn S23, Dvory-Sobol H23, Brandt-Sarif T23, Pang PS23, McHutchison JG23, Reddy KR24, Afdhal N25; SOLAR-1 Investigators. Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682-4. doi: 10.1053/j.gastro.2015.05.010. [Epub ahead of print] |
|
| |
| 585. | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis |
| |
Muir AJ1, Poordad F2, Lalezari J3, Everson G4, Dore GJ5, Herring R6, Sheikh A7, Kwo P8, Hézode C9, Pockros PJ10, Tran A11, Yozviak J12, Reau N13, Ramji A14, Stuart K15, Thompson AJ16, Vierling J17, Freilich B18, Cooper J19, Ghesquiere W20, Yang R21, McPhee F22, Hughes EA21, Swenson ES22, Yin PD22. JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868. |
|
| |
| 586. | Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection |
| |
Poordad F1, Sievert W2, Mollison L3, Bennett M4, Tse E5, Bräu N6, Levin J7, Sepe T8, Lee SS9, Angus P10, Conway B11, Pol S12, Boyer N13, Bronowicki JP14, Jacobson I15, Muir AJ16, Reddy KR17, Tam E18, Ortiz-Lasanta G19, de Lédinghen V20, Sulkowski M21, Boparai N22, McPhee F23, Hughes E22, Swenson ES23, Yin PD23; UNITY-1 Study Group. JAMA. 2015 May 5;313(17):1728-35. doi: 10.1001/jama.2015.3860. |
|
| |
| 587. | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials |
| |
Alqahtani SA1, Afdhal N2, Zeuzem S3, Gordon S4, Mangia A5, Kwo P6, Fried M7, Yang JC8, Ding X8, Pang PS8, McHutchison JG8, Pound D9, Reddy KR10, Marcellin P11, Kowdley KV12, Sulkowski M1. Hepatology. 2015 May 11. doi: 10.1002/hep.27890. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 592. | Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients with Hepatitis C, Regardless of Response to Antiviral Therapy |
| |
Lens S1, Rincón D2, García-Retortillo M3, Albillos A4, Calleja JL5, Bañares R2, González-Abraldes J6, Bosch J7, Sanchez-Tapias JM1, Forns X1, García-Pagán JC8. Clin Gastroenterol Hepatol. 2015 Apr 22. pii: S1542-3565(15)00415-2. doi: 10.1016/j.cgh.2015.04.013. [Epub ahead of print] |
|
| |
|
|
| |
| 594. | Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic HCV Genotype 1, 4, or 6 Infection: A Randomized Trial |
| |
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Ann Intern Med. 2015 Apr 24. doi: 10.7326/M15-0785. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 598. | Telaprevir- and Boceprevir-Based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study |
| |
Verna EC1, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA; for the CRUSH-C Consortium. Transplantation. 2015 Feb 24. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 603. | Grazoprevir/Elbasvir plus Ribavirin For Chronic HCV Genotype-1 Infection After Failure of Combination Therapy Containing a Direct-Acting Antiviral Agent |
| |
Forns X1, Gordon SC2, Zuckerman E3, Lawitz E4, Calleja JL5, Hofer H6, Gilbert C7, Palcza J7, Howe AY7, DiNubile MJ7, Robertson MN7, Wahl J7, Barr E7, Buti M8. J Hepatol. 2015 Apr 17. pii: S0168-8278(15)00291-3. doi: 10.1016/j.jhep.2015.04.009. [Epub ahead of print] |
|
| |
|
|
| |
| 605. | Hepatitis C virus reinfection and spontaneous clearance of reinfection - the InC3 study |
| |
Sacks-Davis R1, Grebely J2, Dore GJ2, Osburn W3, Cox AL3, Rice TM4, Spelman T1, Bruneau J5, Prins M6, Kim AY7, McGovern BH8, Shoukry NH5, Schinkel J9, Allen TM7, Morris M4, Hajarizadeh B2, Maher L2, Lloyd AR10, Page K4, Hellard M1; InC3 study grou J Infect Dis. 2015 Apr 15. pii: jiv220. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 618. | A comparative study of patients' knowledge about hepatitis C in the United States and in urban and rural China |
| |
Wu E1, Chen X, Guan Z, Cao C, Rao H, Feng B, Chan M, Fu S, Lin A, Wei L, Lok AS. Hepatol Int. 2015 Jan;9(1):58-66. doi: 10.1007/s12072-014-9559-z. Epub 2014 Jul 31. |
|
| |
|
|
| |
|
|
| |
| 621. | |
| |
Sep 9;10(3):164-71. doi: 10.1108/IJPH-11-2013-0051. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 632. | Integrated Care Increases Treatment and Improves Outcomes of Patients with Chronic HCV Infection and Psychiatric Illness or Substance Abuse |
| |
Ho SB1, Bräu N2, Cheung R3, Liu L4, Sanchez C5, Sklar M4, Phelps TE6, Marcus SG7, Wasil MM5, Tisi A7, Huynh L6, Robinson SK4, Gifford A8, Asch SM3, Groessl EJ4. Clin Gastroenterol Hepatol. 2015 Feb 24. pii: S1542-3565(15)00161-5. doi: 10.1016/j.cgh.2015.02.022. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 637. | Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection |
| |
Osinusi A1, Townsend K2, Kohli A3, Nelson A4, Seamon C5, Meissner EG6, Bon D7, Silk R8, Gross C8, Price A8, Sajadi M9, Sidharthan S5, Sims Z5, Herrmann E7, Hogan J10, Teferi G10, Talwani R9, Proschan M11, Jenkins V12, Kleiner DE13, Wood BJ14, Subramanian GM15, Pang PS15, McHutchison JG15, Polis MA2, Fauci AS2, Masur H5, Kottilil S4. JAMA. 2015 Feb 23. doi: 10.1001/jama.2015.1373. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 643. | Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders |
| |
Jensen D1, Sherman KE2, Hézode C3, Pol S4, Zeuzem S5, Ledinghen V6, Tran A7, Elkhashab M8, Younes ZH9, Kugelmas M10, Mauss S11, Everson G12, Luketic V13, Vierling J14, Serfaty L15, Brunetto M16, Heo J17, Bernstein D18, McPhee F19, Hennicken D20, Mendez P21, Hughes E21, Noviello S21; on behalf of the HALLMARK-QUAD Study Team. J Hepatol. 2015 Feb 19. pii: S0168-8278(15)00125-7. doi: 10.1016/j.jhep.2015.02.018. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 649. | Findings from Integrated Behavioral and Biologic Survey among Males Who Inject Drugs (MWID) - Vietnam, 2009-2010: Evidence of the Need for an Integrated Response to HIV, Hepatitis B Virus, and Hepatitis C Virus |
| |
Nadol P1, O'connor S2, Duong H3, Le LV3, Thang PH4, Tram TH4, Ha HT4, Mcconnell MS3, Partridge J5, Kaldor J6, Law M6, Nguyen TA4. PLoS One. 2015 Feb 18;10(2):e0118304. doi: 10.1371/journal.pone.0118304. eCollection 2015. |
|
| |
| 650. | Hepatitis C |
| |
Webster DP1, Klenerman P2, Dusheiko GM3. Lancet. 2015 Feb 13. pii: S0140-6736(14)62401-6. doi: 10.1016/S0140-6736(14)62401-6. [Epub ahead of print] |
|
| |
| 651. | Risk of infections during interferon-based treatment in patients with chronic HCV infection and advanced hepatic fibrosis |
| |
Maan R1, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Manns MP, Zeuzem S, Janssen HL, de Knegt RJ, Veldt BJ. J Gastroenterol Hepatol. 2015 Feb 13. doi: 10.1111/jgh.12929. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 654. | Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study |
| |
Molina JM1, Orkin C2, Iser DM3, Zamora FX4, Nelson M5, Stephan C6, Massetto B7, Gaggar A7, Ni L7, Svarovskaia E7, Brainard D7, Subramanian GM7, McHutchison JG7, Puoti M8, Rockstroh JK9; for the PHOTON-2 study team. Lancet. 2015 Feb 3. pii: S0140-6736(14)62483-1. doi: 10.1016/S0140-6736(14)62483-1. [Epub ahead of print] |
|
| |
| 655. | Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir |
| |
Menon R1, Badri P2, Wang T2, Polepally A2, Zha J2, Khatri A2, Wang H2, Hu B2, Coakley E2, Podsadecki T2, Awni W2, Dutta S2. J Hepatol. 2015 Jan 31. pii: S0168-8278(15)00057-4. doi: 10.1016/j.jhep.2015.01.026. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 660. | All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study |
| |
Nelson DR1, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA; on behalf of the ALLY-3 Study Team. Hepatology. 2015 Jan 23. doi: 10.1002/hep.27726. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 665. | Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study |
| |
Kohli A1, Osinusi A2, Sims Z3, Nelson A4, Meissner EG4, Barrett LL5, Bon D6, Marti MM4, Silk R7, Kotb C7, Gross C7, Jolley TA4, Sidharthan S3, Petersen T3, Townsend K4, Egerson D7, Kapoor R7, Spurlin E4, Sneller M4, Proschan M8, Herrmann E6, Kwan R4, Teferi G9, Talwani R10, Diaz G11, Kleiner DE12, Wood BJ13, Chavez J9, Abbott S9, Symonds WT14, Subramanian GM14, Pang PS14, McHutchison J14, Polis MA4, Fauci AS4, Masur H3, Kottilil S15. Lancet. 2015 Jan 12. pii: S0140-6736(14)61228-9. doi: 10.1016/S0140-6736(14)61228-9. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 670. | Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term |
| |
Macías J1, Mancebo M, Márquez M, Merino D, Téllez F, Rivero A, von Wichmann MA, López-Cortés LF, Merchante N, Santos J, Raffo M, Pérez-Pérez M, Camacho Á, Iribarren JA, Pineda JA. Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 680. | Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies |
| |
Lenz O1, Verbinnen T2, Fevery B2, Tambuyzer L2, Vijgen L2, Peeters M2, Buelens A2, Ceulemans H2, Beumont M2, Picchio G3, Meyer SD2. J Hepatol. 2014 Nov 28. pii: S0168-8278(14)00881-2. doi: 10.1016/j.jhep.2014.11.032. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 685. | An Interferon-free Antiviral Regimen for HCV after Liver Transplantation |
| |
Kwo PY1, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X N Engl J Med. 2014 Nov 11. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 689. | Accuracy of real-time tissue elastography for the evaluation of hepatic fibrosis in patients with chronic hepatitis B: a prospective multicenter study |
| |
Wu T1, Ren J, Cong SZ, Meng FK, Yang H, Luo Y, Lin HJ, Sun Y, Wang XY, Pei SF, Zheng Y, He Y, Chen Y, Hu Y, Yang N, Li P, Kudo M, Zheng RQ. Dig Dis. 2014;32(6):791-9. doi: 10.1159/000368024. Epub 2014 Oct 29. |
|
| |
|
|
| |
|
|
| |
| 692. | Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation |
| |
Charlton M1, Gane E2, Manns MP3, Brown RS Jr4, Curry MP5, Kwo PY6, Fontana RJ7, Gilroy R8, Teperman L9, Muir AJ10, McHutchison JG11, Symonds WT11, Brainard D11, Kirby B11, Dvory-Sobol H11, Denning J11, Arterburn S11, Samuel D12, Forns X13, Terrault NA14. Gastroenterology. 2014 Oct 7. pii: S0016-5085(14)01194-9. doi: 10.1053/j.gastro.2014.10.001. [Epub ahead of print] |
|
| |
| 693. | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies |
| |
Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print] |
|
| |
| 694. | Concordance of Sustained Virologic Response 4, 12, and 24 Weeks Post-Treatment With Sofosbuvir-Containing Regimens for Hepatitis C Virus |
| |
Yoshida EM1, Sulkowski MS, Gane EJ, Herring RW Jr, Ratziu V, Ding X, Wang J, Chuang SM, Ma J, McNally J, Stamm LM, Brainard DM, Symonds WT, McHutchison JG, Beavers KL, Jacobson IM, Reddy KR, Lawitz E. Hepatology. 2014 Oct 14. doi: 10.1002/hep.27366. [Epub ahead |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 699. | Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies |
| |
Manns MP1, Fried MW, Zeuzem S, Jacobson IM, Forns X, Poordad F, Peeters M, Fu M, Lenz O, Ouwerkerk-Mahadevan S, Jessner W, Scott JA, Kalmeijer R, De La Rosa G, Sinha R, Beumont-Mauviel M. J Viral Hepat. 2014 Nov 3. doi: 10.1111/jvh.12346. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 703. | Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials |
| |
Svarovskaia ES1, Dvory-Sobol H1, Parkin N2, Hebner C1, Gontcharova V1, Martin R1, Ouyang W1, Han B1, Xu S1, Ku K1, Chiu S1, Gane E3, Jacobson IM4, Nelson DR5, Lawitz E6, Wyles DL7, Bekele N1, Brainard D1, Symonds WT1, McHutchison JG1, Miller MD1, Mo H1. Clin Infect Dis. 2014 Sep 28. pii: ciu697. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 711. | What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? |
| |
McDonald SA1, Innes HA2, Hayes PC3, Dillon JF4, Mills PR5, Goldberg DJ6, Barclay S7, Allen S8, Fox R5, Fraser A9, Kennedy N10, Bhattacharyya D11, Hutchinson SJ2. J Hepatol. 2014 Sep 4. pii: S0168-8278(14)00635-7. doi: 10.1016/j.jhep.2014.08.046. [Epub ahead of print] |
|
| |
| 712. | Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic HCV, genotype-1 infected patients |
| |
Meissner EG1, Lee YJ, Osinusi A, Sims Z, Qin J, Sturdevant D, McHutchison J, Subramanian M, Sampson M, Naggie S, Patel K, Remaley AT, Masur H, Kottilil S. Hepatology. 2014 Sep 9. doi: 10.1002/hep.27424. [Epub ahead of print] |
|
| |
| 713. | Simeprevir (TMC435) with Peginterferon/Ribavirin in Patients Coinfected with HCV Genotype-1 and HIV-1: A Phase III Study |
| |
Dieterich D1, Rockstroh JK2, Orkin C3, Gutiérrez F4, Klein MB5, Reynes J6, Shukla U7, Jenkins A8, Lenz O9, Ouwerkerk-Mahadevan S10, Peeters M9, De La Rosa G7, Tambuyzer L9, Jessner W9. Clin Infect Dis. 2014 Sep 5. pii: ciu675. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 717. | Current Practices of Screening for Incident Hepatitis C Virus Infection among HIV- Infected, HCV-Uninfected Individuals in Primary Care |
| |
Freiman JM1, Huang W1, White L2, Geng EH3, Hurt CB4, Taylor LE5, Overton ET6, Cachay ER7, Kitahata MM8, Moore RD9, Rodriguez B10, Mayer KH11, Linas BP12. Clin Infect Dis. 2014 Sep 3. pii: ciu698. [Epub ahead of print] |
|
| |
| 718. | Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C |
| |
Younossi ZM1, Stepanova M2, Henry L3, Gane E4, Jacobson IM5, Lawitz E6, Nelson D7, Gerber L2, Nader F8, Hunt S2. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1349-59.e13. doi: 10.1016/j.cgh.2013.11.032. Epub 2013 Dec 6. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 737. | Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance |
| |
Chang ML1, Tsou YK2, Hu TH3, Lin CH2, Lin WR2, Sung CM2, Chen TH2, Cheng ML4, Chang KC3, Chiu CT2, Yeh CT2, Pang JH5, Shiao MS4. PLoS One. 2014 Aug 14;9(8):e104783. doi: 10.1371/journal.pone.0104783. eCollection 2014. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 741. | Hepatitis C in African Americans |
| |
Saab S1, Jackson Md Facg C2, Nieto DO Facg Facp J3, Francois Md MSc Facg F4. Am J Gastroenterol. 2014 Sep 2. doi: 10.1038/ajg.2014.243. [Epub ahead of print] |
|
| |
|
|
| |
| 743. | Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C |
| |
Lawitz E1, Gruener D, Marbury T, Hill J, Webster L, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Antivir Ther. 2014 Aug 8. doi: 10.3851/IMP2845. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 749. | Modeling viral evolutionary dynamics after telaprevir-based treatment |
| |
Haseltine EL1, De Meyer S2, Dierynck I2, Bartels DJ1, Ghys A2, Davis A1, Zhang EZ1, Tigges AM1, Spanks J1, Picchio G3, Kieffer TL1, Sullivan JC1. PLoS Comput Biol. 2014 Aug 7;10(8):e1003772. doi: 10.1371/journal.pcbi.1003772. eCollection 2014. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 754. | Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz and tenofovir |
| |
Sabo JP1, Kort J1, Ballow C2, Haschke M3, Battegay M3, Fuhr R4, Girlich B5, Schobelock M6, Feifel U7, Lang B8, Li Y1, Elgadi M9. Clin Infect Dis. 2014 Aug 4. pii: ciu616. [Epub ahead of print] |
|
| |
| 755. | Clinical outcomes of compensated and decompensated cirrhosis: A long term study |
| |
Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504. |
|
| |
|
|
| |
| 757. | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study |
| |
Lawitz E1, Sulkowski MS2, Ghalib R3, Rodriguez-Torres M4, Younossi ZM5, Corregidor A6, DeJesus E7, Pearlman B8, Rabinovitz M9, Gitlin N10, Lim JK11, Pockros PJ12, Scott JD13, Fevery B14, Lambrecht T15, Ouwerkerk-Mahadevan S14, Callewaert K14, Symonds WT16, Picchio G17, Lindsay KL17, Beumont M14, Jacobson IM18. Lancet. 2014 Jul 26. pii: S0140-6736(14)61036-9. doi: 10.1016/S0140-6736(14)61036-9. [Epub ahead of print] |
|
| |
| 758. | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study |
| |
Manns M1, Pol S2, Jacobson IM3, Marcellin P4, Gordon SC5, Peng CY6, Chang TT7, Everson GT8, Heo J9, Gerken G10, Yoffe B11, Towner WJ12, Bourliere M13, Metivier S14, Chu CJ15, Sievert W16, Bronowicki JP17, Thabut D18, Lee YJ19, Kao JH20, McPhee F21, Kopit J21, Mendez P22, Linaberry M22, Hughes E22, Noviello S22; on behalf of the HALLMARK-DUAL Study Team. Lancet. 2014 Jul 26. pii: S0140-6736(14)61059-X. doi: 10.1016/S0140-6736(14)61059-X. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 761. | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study |
| |
Hézode C1, Hirschfield GM2, Ghesquiere W3, Sievert W4, Rodriguez-Torres M5, Shafran SD6, Thuluvath PJ7, Tatum HA8, Waked I9, Esmat G10, Lawitz EJ11, Rustgi VK12, Pol S13, Weis N14, Pockros PJ15, Bourlière M16, Serfaty L17, Vierling JM18, Fried MW19, Weiland O20, Brunetto MR21, Everson GT22, Zeuzem S23, Kwo PY24, Sulkowski M25, Bräu N26, Hernandez D27, McPhee F27, Wind-Rotolo M28, Liu Z29, Noviello S28, Hughes EA28, Yin PD27, Schnittman S27. Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print] |
|
| |
|
|
| |
| 763. | Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: Multicenter prospective observational study (REPENTINA 3) |
| |
Loras C1, Gisbert JP2, Saro MC3, Piqueras M4, Sánchez-Montes C5, Barrio J6, Ordás I7, Montserrat A8, Ferreiro R9, Zabana Y1, Chaparro M2, Fernández-Bañares F1, Esteve M10; for the REPENTINA study, GETECCU group (Grupo Español de trabajo de Enfermedades de Crohn y Colitis Ulcerosa). J Crohns Colitis. 2014 Jul 19. pii: S1873-9946(14)00206-2. doi: 10.1016/j.crohns.2014.06.009. [Epub ahead of print] |
|
| |
| 764. | Costs of Telaprevir-based Triple Therapy for Hepatitis C: $189,000 per Sustained Virologic Response |
| |
Bichoupan K1, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Perumalswami PV, Schiano TD, Odin JA, Liu L, Moskowitz AJ, Dieterich DT, Branch AD. Hepatology. 2014 Jul 28. doi: 10.1002/hep.27340. [Epub ahead of print] |
|
| |
| 765. | Delivery of treatment for hepatitis C virus infection in the primary care setting |
| |
Baker D1, Alavi M, Erratt A, Hill S, Balcomb A, Hallinan R, Siriragavan S, Richmond D, Smart J, Keats J, Doong N, Marks P, Grebely J, Dore GJ. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1003-9. doi: 10.1097/MEG.0000000000000150. |
|
| |
|
|
| |
| 767. | Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection |
| |
Sulkowski MS1, Naggie S2, Lalezari J3, Fessel WJ4, Mounzer K5, Shuhart M6, Luetkemeyer AF7, Asmuth D8, Gaggar A9, Ni L9, Svarovskaia E9, Brainard DM9, Symonds WT9, Subramanian GM9, McHutchison JG9, Rodriguez-Torres M10, Dieterich D11; PHOTON-1 Investigators. JAMA. 2014 Jul 23-30;312(4):353-61. doi: 10.1001/jama.2014.7734. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 772. | Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C |
| |
Bronowicki JP1, Ratziu V2, Gadano A3, Thuluvath PJ4, Bessone F5, Martorell CT6, Pol S7, Terg R8, Younes Z9, He B10, Eley T10, Cohen D11, Yu F11, Hernandez D11, McPhee F11, Mendez P10, Hughes E10. J Hepatol. 2014 Jul 16. pii: S0168-8278(14)00480-2. doi: 10.1016/j.jhep.2014.07.011. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 787. | Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study |
| |
Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print] |
|
| |
|
|
| |
| 789. | Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program |
| |
Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 792. | Simeprevir (TMC435) once daily with peginterferon ?-2b and ribavirin in patients with genotype-1 hepatitis-C virus infection: the CONCERTO-4 study |
| |
Kumada H1, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Hepatol Res. 2014 Jun 24. doi: 10.1111/hepr.12375. [Epub ahead of print] |
|
| |
|
|
| |
| 794. | Sustained Virological Response with Telaprevir in 1078 Patients With Advanced Hepatitis C: The International Telaprevir Access Program |
| |
Colombo M1, Strasser SI2, Moreno C3, Ferreira PA4, Urbanek P5, Fernández I6, Abdurakmonov D7, Streinu-Cercel A8, Verheyen A9, Iraqi W10, DeMasi R11, Hill A12, Lonjon-Domanec I10, Wedemeyer H13. J Hepatol. 2014 Jun 16. pii: S0168-8278(14)00400-0. doi: 10.1016/j.jhep.2014.06.005. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 799. | Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model |
| |
Ikeda K1, Kawamura Y, Kobayashi M, Fukushima T, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Oncology. 2014 Jun 7;86(5-6):295-302. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 803. | IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response |
| |
Lin JC1, Habersetzer F2, Rodriguez-Torres M3, Afdhal N4, Lawitz EJ5, Paulson MS6, Zhu Y6, Subramanian GM6, McHutchison JG6, Sulkowski M7, Wyles DL1, Schooley RT1. J Infect Dis. 2014 Jun 6. pii: jiu325. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 806. | Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial |
| |
Manns M1, Marcellin P2, Poordad F3, de Araujo ES4, Buti M5, Horsmans Y6, Janczewska E7, Villamil F8, Scott J9, Peeters M10, Lenz O10, Ouwerkerk-Mahadevan S11, De La Rosa G12, Kalmeijer R12, Sinha R10, Beumont-Mauviel M10. Lancet. 2014 Jun 3. pii: S0140-6736(14)60538-9. doi: 10.1016/S0140-6736(14)60538-9. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 809. | Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial |
| |
Jacobson IM1, Dore GJ2, Foster GR3, Fried MW4, Radu M5, Rafalsky VV6, Moroz L7, Craxi A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, De La Rosa G11, Kalmeijer R11, Scott J12, Sinha R9, Beumont-Mauviel M9. Lancet. 2014 Jun 3. pii: S0140-6736(14)60494-3. doi: 10.1016/S0140-6736(14)60494-3. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 816. | Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C |
| |
Elkrief L1, Chouinard P, Bendersky N, Hajage D, Larroque B, Babany G, Kutala B, Francoz C, Boyer N, Moreau R, Durand F, Marcellin P, Rautou PE, Valla D. Hepatology. 2014 May 20. doi: 10.1002/hep.27228. [Epub ahead of print] |
|
| |
|
|
| |
| 818. | Sustained Virologic Response Rates With Telaprevir-Based Therapy in Treatment-Naive Patients Evaluated by Race or Ethnicity |
| |
Flamm SL1, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. J Clin Gastroenterol. 2014 May 13. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 826. | Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters |
| |
van der Meer AJ1, Hansen BE, Fattovich G, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Manns MP, Ieluzzi D, Zeuzem S, Hofmann WP, de Knegt RJ, Veldt BJ, Janssen HL. Gut. 2014 May 9. doi: 10.1136/gutjnl-2013-305357. [Epub ahead of print] |
|
| |
| 827. | ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection |
| |
Andreone P1, Colombo MG2, Enejosa JV3, Koksal I4, Ferenci P5, Maieron A6, Müllhaupt B7, Horsmans Y8, Weiland O9, Reesink HW10, Rodrigues L Jr3, Hu YB3, Podsadecki T3, Bernstein B3. Gastroenterology. 2014 May 9. pii: S0016-5085(14)00603-9. doi: 10.1053/j.gastro.2014.04.045. [Epub ahead of print] |
|
| |
| 828. | Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3 |
| |
Zeuzem S1, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; the VALENCE Investigators. N Engl J Med. 2014 May 4. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 831. | A US Multicenter Study of Hepatitis C Treatment of Liver Transplant Recipients with Protease-Inhibitor Triple Therapy |
| |
Burton JR Jr1, O'Leary JG2, Verna EC3, Saxena V4, Dodge JL4, Stravitz RT5, Levitsky J6, Trotter JF2, Everson GT1, Brown RS Jr3, Terrault NA7. J Hepatol. 2014 May 3. pii: S0168-8278(14)00300-6. doi: 10.1016/j.jhep.2014.04.037. [Epub ahead of print] |
|
| |
| 832. | Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model - Arizona and utah, 2012-2014 |
| |
Mitruka K, Thornton K, Cusick S, Orme C, Moore A, Manch RA, Box T, Carroll C, Holtzman D, Ward JW; Division of Viral Hepatitis, National Center for National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. MMWR Morb Mortal Wkly Rep. 2014 May 9;63(18):393-8. |
|
| |
|
|
| |
|
|
| |
| 835. | All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection |
| |
Wyles DL1, Rodriguez-Torres M, Lawitz E, Shiffman ML, Pol S, Herring RW, Massetto B, Kanwar B, Trenkle JD, Pang PS, Zhu Y, Mo H, Brainard DM, Subramanian GM, McHutchison JG, Habersetzer F, Sulkowski MS. Hepatology. 2014 Feb 5. doi: 10.1002/hep.27053. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 838. | ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type |
| |
Matsuura K1, Tanaka Y, Watanabe T, Fujiwara K, Orito E, Kurosaki M, Izumi N, Sakamoto N, Enomoto N, Yatsuhashi H, Kusakabe A, Shinkai N, Nojiri S, Joh T, Mizokami M. J Viral Hepat. 2013 Sep 3. doi: 10.1111/jvh.12171. [Epub ahead of print] |
|
| |
| 839. | Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy |
| |
Miller MH1, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR, Fox R, Hayes PC, Leen C, Millson C, Ryder SD, Tait J, Ustianowski A, Dillon JF. Aliment Pharmacol Ther. 2014 Apr 22. doi: 10.1111/apt.12764. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 845. | Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection |
| |
Afdhal N1, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; the ION-1 Investigators. N Engl J Med. 2014 Apr 11. [Epub ahead of print] |
|
| |
|
|
| |
| 847. | Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection |
| |
Afdhal N1, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11. |
|
| |
| 848. | Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis |
| |
Kowdley KV1, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; the ION-3 Investigators. N Engl J Med. 2014 Apr 10. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 859. | Boceprevir In Liver Transplant Recipients |
| |
Saab S1, Manne V, Bau S, Reynolds JA, Allen R, Goldstein L, Durazo F, El-Kabany M, Han S, Busuttil RW. Liver Int. 2014 Mar 26. doi: 10.1111/liv.12548. [Epub ahead of print] |
|
| |
|
|
| |
| 861. | The Effect of Mild to Moderate Renal Impairment on the Pharmacokinetics of the Nucleoside Analog Hepatitis C Virus Polymerase Inhibitor Mericitabine |
| |
Haznedar J1, Moreira S, Marbury T, Robson R, Smith W, Kulkarni R, Munson ML, Thommes JA, Lemenuel-Diot A, Washington C, Smith P, Chen YC. Drug Dev Res. 2013 Dec 26. doi: 10.1002/ddr.21166. [Epub ahead of print] |
|
| |
| 862. | Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188) |
| |
Deuffic-Burban S1, Schwarzinger M2, Obach D3, Mallet V4, Pol S5, Pageaux GP6, Canva V7, Deltenre P8, Roudot-Thoraval F9, Larrey D10, Dhumeaux D11, Mathurin P12, Yazdanpanah Y13. J Hepatol. 2014 Mar 17. pii: S0168-8278(14)00155-X. doi: 10.1016/j.jhep.2014.03.011. [Epub ahead of print] |
|
| |
|
|
| |
| 864. | Barriers to HCV treatment in the era of triple therapy: A prospective multi-centered study in clinical practice |
| |
Crespo J1, Cabezas J, Sacristán B, Olcoz JL, Pérez R, de la Vega J, García R, García-Pajares F, Sáez-Royuela F, González JM, Jiménez F, Rodríguez S, Cuadrado A, López-Arias MJ, García I, Milla A, García-Riesco E, Muñoz M, Sánchez-Antolín G, Jorquera F. Liver Int. 2014 Mar 20. doi: 10.1111/liv.12536. [Epub ahead of print] |
|
| |
|
|
| |
| 866. | Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C |
| |
Ponziani FR1, Viganò R2, Iemmolo RM3, Donato MF4, Rendina M5, Toniutto P6, Pasulo L7, Morelli MC8, Burra P9, Miglioresi L10, Merli M11, Di Paolo D12, Fagiuoli S7, Gasbarrini A13, Pompili M13; on behalf of AISF RECOLT-C Group, Belli L, Gerunda GE, Marino M, Montalti R, Di Benedetto F, De Ruvo N, Rigamonti C, Colombo M, Rossi G, Di Leo A, Lupo L, Memeo V, Bringiotti R, Zappimbulso M, Bitetto D, Vero V, Colpani M, Fornasiere E, Pinna AD, Morelli MC, Bertuzzo V, De Martin E, Senzolo M, Ettorre GM, Visco-Comandini U, Antonucci G, Angelico M, Tisone G, Giannelli V, Giusto M. Dig Liver Dis. 2014 Mar 10. pii: S1590-8658(14)00207-2. doi: 10.1016/j.dld.2014.01.157. [Epub ahead of print] |
|
| |
|
|
| |
| 868. | Peginterferon and Ribavirin for Treatment of Recurrent Hepatitis C Disease in HCV-HIV Coinfected Liver Transplant Recipients |
| |
Terrault N1, Reddy KR, Poordad F, Curry M, Schiano T, Johl J, Shaikh O, Dove L, Shetty K, Millis M, Schiff E, Regenstein F, Barnes D, Barin B, Peters M, Roland M, Stock P; for the HIVTR Investigators. Am J Transplant. 2014 Mar 17. doi: 10.1111/ajt.12668. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 873. | Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection |
| |
Kumada H1, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Hepatology. 2014 Mar 6. doi: 10.1002/hep.27113. [Epub ahead of print] |
|
| |
| 874. | Simeprevir with Peginterferon and Ribavirin Leads to High Rates of SVR in Patients with HCV Genotype 1 Who Relapsed After Previous Therapy: a Phase 3 Trial |
| |
Forns X1, Lawitz E2, Zeuzem S3, Gane E4, Bronowicki JP5, Andreone P6, Horban A7, Brown A8, Peeters M9, Lenz O9, Ouwerkerk-Mahadevan S10, Scott J11, De La Rosa G12, Kalmeijer R12, Sinha R9, Beumont-Mauviel M9. Gastroenterology. 2014 Mar 3. pii: S0016-5085(14)00293-5. doi: 10.1053/j.gastro.2014.02.051. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 898. | Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection |
| |
Picchio G1, De Meyer S2, Dierynck I2, Ghys A2, Gritz L3, Kieffer TL3, Bartels DJ3, Witek J4, Bengtsson L3, Luo D4, Kauffman RS3, Adda N5, Sarrazin C6. J Clin Virol. 2014 Jan 6. pii: S1386-6532(13)00542-8. doi: 10.1016/j.jcv.2013.12.011. [Epub ahead of print] |
|
| |
|
|
| |
| 900. | Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders |
| |
Lok AS1, Gardiner DF2, Hézode C3, Lawitz EJ4, Bourlière M5, Everson GT6, Marcellin P7, Rodriguez-Torres M8, Pol S9, Serfaty L10, Eley T2, Huang SP11, Li J11, Wind-Rotolo M11, Yu F12, McPhee F12, Grasela DM2, Pasquinelli C2. J Hepatol. 2013 Oct 26. pii: S0168-8278(13)00744-7. doi: 10.1016/j.jhep.2013.10.019. [Epub ahead of print] |
|
| |
| 901. | Acute hepatitis C: A 24 week-course of Peg-Interferon alpha-2b versus a 12 week-course of Peg-Interferon alpha-2b alone or with ribavirin |
| |
Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Perri GD, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Hepatology. 2014 Jan 18. doi: 10.1002/hep.26991. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
| 904. | A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4 |
| |
Vince B1, Hill JM2, Lawitz EJ3, O'Riordan W4, Webster LR5, Gruener DM6, Mofsen RS7, Murillo A8, Donovan E9, Chen J9, McCarville JF9, Sullivan-Bólyai JZ9, Mayers D9, Zhou XJ10. J Hepatol. 2014 Jan 13. pii: S0168-8278(14)00014-2. doi: 10.1016/j.jhep.2014.01.003. [Epub ahead of print] |
|
| |
| 905. | Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 |
| |
Kris V. Kowdley, M.D., Eric Lawitz, M.D., Fred Poordad, M.D., Daniel E. Cohen, M.D., David R. Nelson, M.D., Stefan Zeuzem, M.D., Gregory T. Everson, M.D., Paul Kwo, M.D., Graham R. Foster, F.C.R.P., Mark S. Sulkowski, M.D., Wangang Xie, Ph.D., Tami Pilot-Matias, Ph.D., George Liossis, B.A., Lois Larsen, Ph.D., Amit Khatri, Ph.D., Thomas Podsadecki, M.D., and Barry Bernstein, M.D. |
|
| |
|
|
| |
|
|
| |
| 908. | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection |
| |
Mark S. Sulkowski, M.D., David F. Gardiner, M.D., Maribel Rodriguez-Torres, M.D., K. Rajender Reddy, M.D., Tarek Hassanein, M.D., Ira Jacobson, M.D., Eric Lawitz, M.D., Anna S. Lok, M.D., Federico Hinestrosa, M.D., Paul J. Thuluvath, M.D., Howard Schwartz, M.D., David R. Nelson, M.D., Gregory T. Everson, M.D., Timothy Eley, Ph.D., Megan Wind-Rotolo, Ph.D., Shu-Pang Huang, Ph.D., Min Gao, Ph.D., Dennis Hernandez, Ph.D., Fiona McPhee, Ph.D., Diane Sherman, M.S., Robert Hindes, M.D., William Symonds, Pharm.D., Claudio Pasquinelli, M.D., Ph.D., and Dennis M. Grasela, Pharm.D., Ph.D. for the AI444040 Study Group |
|
| |
|
|
| |
|
|
| |
| 911. | Hepatitis C virus and type 1 diabetes |
| |
Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, Antonelli A. Clin Ter. 2013;164(5):e437-44. doi: 10.7417/CT.2013.1624. |
|
| |
|
|
| |
|
|
| |
|
|
| |
| 915. | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial |
| |
Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Lancet. 2013 Nov 1. pii: S0140-6736(13)62121-2. doi: 10.1016/S0140-6736(13)62121-2. [Epub ahead of print] |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 921. | Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies |
| |
Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network. J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424. |
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 928. | Hepatitis C and alcohol exacerbate liver injury by suppression of FOXO3 |
| |
Tumurbaatar B, Tikhanovich I, Li Z, Ren J, Ralston R, Kuravi S, Campbell R, Chaturvedi G, Huang TT, Zhao J, Hao J, O'Neil M, Weinman SA. Am J Pathol. 2013 Dec;183(6):1803-14. doi: 10.1016/j.ajpath.2013.08.013. Epub 2013 Nov 11. |
|
| |
|
|
| |
|
|
| |
| 931. | Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of Sustained Viral Response in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis |
| |
Rodriguez-Torres M1, Stoehr A2, Gane EJ3, Serfaty L4, Lawitz E5, Zhou A6, Bourque M6, Bhanja S6, Strizki J6, Barnard RJ6, Hwang PM6, Dinubile MJ6, Mobashery N7. Clin Gastroenterol Hepatol. 2013 Oct 10. pii: S1542-3565(13)01519-X. doi: 10.1016/j.cgh.2013.09.067. [Epub ahead of print] |
|
| |
| 932. | α-Fetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype |
| |
Shimada N, Tsubota A, Atsukawa M, Abe H, Ika M, Kato K, Sato Y, Kondo C, Sakamoto C, Tanaka Y, Aizawa Y. J Med Virol. 2013 Oct 28. doi: 10.1002/jmv.23824. [Epub ahead of print] |
|
| |
|
|
| |
| 934. | Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy |
| |
Crismale JF, Martel-Laferrière V, Bichoupan K, Schonfeld E, Pappas A, Wyatt C, Odin JA, Liu LU, Schiano TD, Perumalswami PV, Bansal M, Dieterich DT, Branch AD. Liver Int. 2013 Oct 1. doi: 10.1111/liv.12342. [Epub ahead of print] |
|
| |
| 935. | Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial |
| |
Zeuzem S1, Berg T2, Gane E3, Ferenci P4, Foster GR5, Fried MW6, Hezode C7, Hirschfield GM8, Jacobson I9, Nikitin I10, Pockros PJ11, Poordad F12, Scott J13, Lenz O14, Peeters M14, Sekar V15, De Smedt G14, Sinha R14, Beumont-Mauviel M14. Gastroenterology. 2013 Nov 1. pii: S0016-5085(13)01576-X. doi: 10.1053/j.gastro.2013.10.058. [Epub ahead of print] |
|
| |
|
|
| |
| | | | |
